Gordon B Mills

List of Publications by Year in Descending Order

821 papers	118,538 citations	164 h-index	326 g-index
873 ext. papers	147,044 ext. citations	11.9 avg, IF	8.11 L-index

#	Paper	IF	Citations
821	Whole-chromosome arm acquired uniparental disomy in cancer development is a consequence of isochromosome formation.. *Neoplasia*, **2022**, 25, 9-17	6.4	0
820	WEE1 inhibition induces anti-tumor immunity by activating ERV and the dsRNA pathway. *Journal of Experimental Medicine*, **2022**, 219,	16.6	4
819	Profiling of immune features to predict immunotherapy efficacy.. *Innovation(China)*, **2022**, 3, 100194	17.8	2
818	An omic and multidimensional spatial atlas from serial biopsies of an evolving metastatic breast cancer.. *Cell Reports Medicine*, **2022**, 3, 100525	18	0
817	Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer.. *Nature Reviews Cancer*, **2022**,	31.3	9
816	MITI minimum information guidelines for highly multiplexed tissue images.. *Nature Methods*, **2022**, 19, 262-267	21.6	2
815	A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma.. *Gynecologic Oncology Reports*, **2022**, 40, 100974	1.3	1
814	A multi-encoder variational autoencoder controls multiple transformational features in single-cell image analysis.. *Communications Biology*, **2022**, 5, 255	6.7	0
813	A functional genomic approach to actionable gene fusions for precision oncology.. *Science Advances* , **2022**, 8, eabm2382	14.3	0
812	Anti-tumor Activity of a Mitochondrial Targeted HSP90 Inhibitor in Gliomas.. *Clinical Cancer Research*, **2022**,	12.9	2
811	Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers.. *Npj Breast Cancer*, **2022**, 8, 64	7.8	
810	Mechanical stress signaling in pancreatic cancer cells triggers p38 MAPK- and JNK-dependent cytoskeleton remodeling and promotes cell migration via Rac1/Cdc42/Myosin II. *Molecular Cancer Research*, **2021**,	6.6	6
809	Interleukin enhancer-binding factor 2 promotes cell proliferation and DNA damage response in metastatic melanoma. *Clinical and Translational Medicine*, **2021**, 11, e608	5.7	5
808	Multiomics analysis of serial PARP inhibitor treated metastatic TNBC inform on rational combination therapies. *Npj Precision Oncology*, **2021**, 5, 92	9.8	1
807	Hormonal modulation of ESR1 mutant metastasis. *Oncogene*, **2021**, 40, 997-1011	9.2	10
806	Landscapes of cellular phenotypic diversity in breast cancer xenografts and their impact on drug response. *Nature Communications*, **2021**, 12, 1998	17.4	12
805	Characterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analytics. *Npj Precision Oncology*, **2021**, 5, 28	9.8	4

804	Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy. *Journal of the National Cancer Institute*, **2021**, 113, 1396-1404	9.7	10
803	An expanded universe of cancer targets. *Cell*, **2021**, 184, 1142-1155	56.2	38
802	Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer. *Clinical Cancer Research*, **2021**, 27, 3243-3252	12.9	1
801	Spatially interacting phosphorylation sites and mutations in cancer. *Nature Communications*, **2021**, 12, 2313	17.4	2
800	Glutaminase inhibition with telaglenastat (CB-839) improves treatment response in combination with ionizing radiation in head and neck squamous cell carcinoma models. *Cancer Letters*, **2021**, 502, 180-188	9.9	10
799	mi-IsoNet: systems-scale microRNA landscape reveals rampant isoform-mediated gain of target interaction diversity and signaling specificity. *Briefings in Bioinformatics*, **2021**, 22,	13.4	2
798	Phase 1 trial of nelfinavir added to standard cisplatin chemotherapy with concurrent pelvic radiation for locally advanced cervical cancer. *Cancer*, **2021**, 127, 2279-2293	6.4	6
797	Clinical and Functional Characterization of Atypical / Mutations in Metastatic Colorectal Cancer. *Clinical Cancer Research*, **2021**, 27, 4587-4598	12.9	4
796	In Situ Tumor Vaccination with Nanoparticle Co-Delivering CpG and STAT3 siRNA to Effectively Induce Whole-Body Antitumor Immune Response. *Advanced Materials*, **2021**, 33, e2100628	24	10
795	Uncoupling of gene expression from copy number presents therapeutic opportunities in aneuploid cancers. *Cell Reports Medicine*, **2021**, 2, 100349	18	0
794	Relevance of circulating hybrid cells as a non-invasive biomarker for myriad solid tumors. *Scientific Reports*, **2021**, 11, 13630	4.9	8
793	Analysis of Primary Tumor Specimens for Evaluation of Cancer Therapeutics. *Annual Review of Cancer Biology*, **2021**, 5, 39-57	13.3	4
792	Modeling Heterogeneity of Triple-Negative Breast Cancer Uncovers a Novel Combinatorial Treatment Overcoming Primary Drug Resistance. *Advanced Science*, **2021**, 8, 2003049	13.6	6
791	Reward Enhances Online Participants' Engagement With a Demanding Auditory Task. *Trends in Hearing*, **2021**, 25, 23312165211025941	3.2	2
790	MEK Inhibition Remodels the Immune Landscape of Mutant Tumors to Overcome Resistance to PARP and Immune Checkpoint Inhibitors. *Cancer Research*, **2021**, 81, 2714-2729	10.1	4
789	Frequent post-operative monitoring of colorectal cancer using individualised ctDNA validated by multiregional molecular profiling. *British Journal of Cancer*, **2021**, 124, 1556-1565	8.7	2
788	Ultrastructure of immunogenic cell death in vivo. *Microscopy and Microanalysis*, **2021**, 27, 1390-1391	0.5	1
787	Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma. *Oncogene*, **2021**, 40, 5590-5599	9.2	6

786	Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance. *Cancer Research*, **2021**, 81, 5230-5241	10.1	1
785	Tumor Therapy: In Situ Tumor Vaccination with Nanoparticle Co-Delivering CpG and STAT3 siRNA to Effectively Induce Whole-Body Antitumor Immune Response (Adv. Mater. 31/2021). *Advanced Materials*, **2021**, 33, 2170244	24	
784	copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer models. *Cell Reports Medicine*, **2021**, 2, 100394	18	2
783	Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer. *Clinical Cancer Research*, **2021**, 27, 6354-6365	12.9	5
782	TOP1 modulation during melanoma progression and in adaptative resistance to BRAF and MEK inhibitors. *Pharmacological Research*, **2021**, 173, 105911	10.2	0
781	BCL-XL blockage in TNBC models confers vulnerability to inhibition of specific cell cycle regulators. *Theranostics*, **2021**, 11, 9180-9197	12.1	0
780	Costimulation of TCR and TLR7/8 promotes Vδ2 T-cell antitumor activity by modulating mTOR pathway and APC function. **2021**, 9,		3
779	Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines. *Cancer Cell*, **2020**, 38, 829-843.e4	24.3	13
778	p85 regulates autophagic degradation of AXL to activate oncogenic signaling. *Nature Communications*, **2020**, 11, 2291	17.4	6
777	Multiplex digital spatial profiling of proteins and RNA in fixed tissue. *Nature Biotechnology*, **2020**, 38, 586-599	44.5	152
776	Prospecting whole cancer genomes.. *Nature Cancer*, **2020**, 1, 273-275	15.4	
775	Comparison of Real-Time Fluorescence Confocal Digital Microscopy With Hematoxylin-Eosin-Stained Sections of Core-Needle Biopsy Specimens. *JAMA Network Open*, **2020**, 3, e200476	10.4	6
774	Fibroblast-tumor cell signaling limits HER2 kinase therapy response via activation of MTOR and antiapoptotic pathways. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 16500-16508	11.5	15
773	RNA-binding protein NONO contributes to cancer cell growth and confers drug resistance as a theranostic target in TNBC. *Theranostics*, **2020**, 10, 7974-7992	12.1	18
772	Proteome Instability Is a Therapeutic Vulnerability in Mismatch Repair-Deficient Cancer. *Cancer Cell* , **2020**, 37, 371-386.e12	24.3	28
771	Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035). *Gynecologic Oncology Reports*, **2020**, 32, 100546	1.3	9
770	Comprehensive assessment of computational algorithms in predicting cancer driver mutations. *Genome Biology*, **2020**, 21, 43	18.3	23
769	Immuno-genomic landscape of osteosarcoma. *Nature Communications*, **2020**, 11, 1008	17.4	77

768	Development of prediction models for lymph node metastasis in endometrioid endometrial carcinoma. *British Journal of Cancer*, **2020**, 122, 1014-1022	8.7	2
767	PIK3CA variants selectively initiate brain hyperactivity during gliomagenesis. *Nature*, **2020**, 578, 166-171	50.4	50
766	Pan-cancer analysis of whole genomes. *Nature*, **2020**, 578, 82-93	50.4	840
765	Downregulation of the Ubiquitin-E3 Ligase RNF123 Promotes Upregulation of the NF-B1 Target SerpinE1 in Aggressive Glioblastoma Tumors. *Cancers*, **2020**, 12,	6.6	13
764	Upregulation of cell surface GD3 ganglioside phenotype is associated with human melanoma brain metastasis. *Molecular Oncology*, **2020**, 14, 1760-1778	7.9	12
763	Predicting Cancer Cell Line Dependencies From the Protein Expression Data of Reverse-Phase Protein Arrays. *JCO Clinical Cancer Informatics*, **2020**, 4, 357-366	5.2	8
762	The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution. *Cell*, **2020**, 181, 236-249	56.2	140
761	Inhibition of the ATM/Chk2 axis promotes cGAS/STING signaling in ARID1A-deficient tumors. *Journal of Clinical Investigation*, **2020**, 130, 5951-5966	15.9	24
760	Genetic alterations and expression characteristics of ARID1A impact tumor immune contexture and survival in early-onset gastric cancer. *American Journal of Cancer Research*, **2020**, 10, 3947-3972	4.4	3
759	MAPK pathway mutations in head and neck cancer affect immune microenvironments and ErbB3 signaling. *Life Science Alliance*, **2020**, 3,	5.8	9
758	Relationship Between Response and Dose in Published, Contemporary Phase I Oncology Trials. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2020**, 18, 428-433	7.3	5
757	Differential expression of MAGEA6 toggles autophagy to promote pancreatic cancer progression. *ELife*, **2020**, 9,	8.9	10
756	Systems approach to rational combination therapy: PARP inhibitors. *Biochemical Society Transactions*, **2020**, 48, 1101-1108	5.1	13
755	Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer. *International Journal of Cancer*, **2020**, 147, 413-422	7.5	19
754	MCP-1/CCR-2 axis in adipocytes and cancer cell respectively facilitates ovarian cancer peritoneal metastasis. *Oncogene*, **2020**, 39, 1681-1695	9.2	20
753	Mutant P53 induces MELK expression by release of wild-type P53-dependent suppression of FOXM1. *Npj Breast Cancer*, **2020**, 6, 2	7.8	6
752	Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers. *British Journal of Cancer*, **2020**, 122, 405-412	8.7	17
751	Proteomic analysis of circulating extracellular vesicles identifies potential markers of breast cancer progression, recurrence, and response. *Science Advances*, **2020**, 6,	14.3	23

750	Analysis of mutational and proteomic heterogeneity of gastric cancer suggests an effective pipeline to monitor post-treatment tumor burden using circulating tumor DNA. *PLoS ONE*, **2020**, 15, e0239966	3.7	1
749	Peritoneal Spread of Ovarian Cancer Harbors Therapeutic Vulnerabilities Regulated by FOXM1 and EGFR/ERBB2 Signaling. *Cancer Research*, **2020**, 80, 5554-5568	10.1	7
748	Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy. *Nature Communications*, **2020**, 11, 4946	17.4	39
747	Candidate biomarker assessment for pharmacological response. *Translational Oncology*, **2020**, 13, 100830	4.9	2
746	Transient commensal clonal interactions can drive tumor metastasis. *Nature Communications*, **2020**, 11, 5799	17.4	9
745	Analysis of Ugandan cervical carcinomas identifies human papillomavirus clade-specific epigenome and transcriptome landscapes. *Nature Genetics*, **2020**, 52, 800-810	36.3	17
744	Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models. *Nature Communications*, **2020**, 11, 3726	17.4	61
743	BRCA1 Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis. *Journal of the National Cancer Institute*, **2020**, 112, 1190-1203	9.7	12
742	Integrated Genomic Characterization of the Human Immunome in Cancer. *Cancer Research*, **2020**, 80, 4854-4867	10.1	4
741	The roles of variants in pancreatic cancer development and their potential impact on cancer immunotherapy. *Autophagy*, **2020**, 16, 1923-1924	10.2	0
740	Synthetic lethal combination targeting BET uncovered intrinsic susceptibility of TNBC to ferroptosis. *Science Advances*, **2020**, 6,	14.3	18
739	Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma. *Clinical Cancer Research*, **2020**, 26, 6039-6050	12.9	9
738	Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer. *Cell Reports*, **2020**, 31, 107502	10.6	28
737	Acquired Uniparental Disomy Regions Are Associated with Disease Outcome in Patients with Oral Cavity and Oropharynx But Not Larynx Cancers. *Translational Oncology*, **2020**, 13, 100763	4.9	0
736	Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts. *Clinical Cancer Research*, **2020**, 26, 3720-3731	12.9	10
735	Verteporfin Inhibits PD-L1 through Autophagy and the STAT1-IRF1-TRIM28 Signaling Axis, Exerting Antitumor Efficacy. *Cancer Immunology Research*, **2020**, 8, 952-965	12.5	25
734	Sex-associated molecular differences for cancer immunotherapy. *Nature Communications*, **2020**, 11, 1779	17.4	57
733	Analysis of mutational and proteomic heterogeneity of gastric cancer suggests an effective pipeline to monitor post-treatment tumor burden using circulating tumor DNA **2020**, 15, e0239966		

732	Analysis of mutational and proteomic heterogeneity of gastric cancer suggests an effective pipeline to monitor post-treatment tumor burden using circulating tumor DNA **2020**, 15, e0239966		
731	Analysis of mutational and proteomic heterogeneity of gastric cancer suggests an effective pipeline to monitor post-treatment tumor burden using circulating tumor DNA **2020**, 15, e0239966		
730	Analysis of mutational and proteomic heterogeneity of gastric cancer suggests an effective pipeline to monitor post-treatment tumor burden using circulating tumor DNA **2020**, 15, e0239966		
729	Comprehensive characterization of circular RNAs in ~ 1000 human cancer cell lines. *Genome Medicine*, **2019**, 11, 55	14.4	70
728	Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion. *European Journal of Cancer*, **2019**, 120, 54-64	7.5	13
727	Identification and validation of a prognostic proteomic signature for cervical cancer. *Gynecologic Oncology*, **2019**, 155, 324-330	4.9	5
726	Impact of Cold Ischemic Time and Freeze-Thaw Cycles on RNA, DNA and Protein Quality in Colorectal Cancer Tissues Biobanking. *Journal of Cancer*, **2019**, 10, 4978-4988	4.5	2
725	Proteomics advances for precision therapy in ovarian cancer. *Expert Review of Proteomics*, **2019**, 16, 841-850	4.2	2
724	Combined MEK and BCL-2/X Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient-Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness. *Molecular Cancer Therapeutics*, **2019**, 18, 642-655	6.1	26
723	Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for -altered head and neck cancer. *Journal of Experimental Medicine*, **2019**, 216, 419-427	16.6	34
722	Advancing Drug Development in Gynecologic Malignancies. *Clinical Cancer Research*, **2019**, 25, 4874-4880	12.9	10
721	TCPA v3.0: An Integrative Platform to Explore the Pan-Cancer Analysis of Functional Proteomic Data. *Molecular and Cellular Proteomics*, **2019**, 18, S15-S25	7.6	25
720	Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options. *Oncotarget*, **2019**, 10, 3533-3546	2.3	12
719	Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy. *Cancer Cell*, **2019**, 35, 851-867.e7	24.3	94
718	The DNA Endonuclease Mus81 Regulates ZEB1 Expression and Serves as a Target of BET4 Inhibitors in Gastric Cancer. *Molecular Cancer Therapeutics*, **2019**, 18, 1439-1450	6.1	6
717	Next-generation characterization of the Cancer Cell Line Encyclopedia. *Nature*, **2019**, 569, 503-508	50.4	962
716	Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium. *Annals of Oncology*, **2019**, 30, 597-603	10.3	74
715	Therapeutic Clues from an Integrated Omic Assessment of East Asian Triple Negative Breast Cancers. *Cancer Cell*, **2019**, 35, 341-343	24.3	4

714	Characterization of Hypoxia-associated Molecular Features to Aid Hypoxia-Targeted Therapy. *Nature Metabolism*, **2019**, 1, 431-444	14.6	76
713	Protein Kinase C Quality Control by Phosphatase PHLPP1 Unveils Loss-of-Function Mechanism in Cancer. *Molecular Cell*, **2019**, 74, 378-392.e5	17.6	18
712	Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. *Cancer*, **2019**, 125, 1963-1972	6.4	22
711	GPNMB augments Wnt-1 mediated breast tumor initiation and growth by enhancing PI3K/AKT/mTOR pathway signaling and catenin activity. *Oncogene*, **2019**, 38, 5294-5307	9.2	12
710	Targeting mitochondria in cancer therapy could provide a basis for the selective anti-cancer activity. *PLoS ONE*, **2019**, 14, e0205623	3.7	14
709	Olaparib and specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. *Lancet Oncology, The*, **2019**, 20, 570-580	21.7	118
708	Breast cancer quantitative proteome and proteogenomic landscape. *Nature Communications*, **2019**, 10, 1600	17.4	84
707	Integrated transcriptomic-genomic tool Texomer profiles cancer tissues. *Nature Methods*, **2019**, 16, 401-406	25.6	4
706	Prospective Clinical Sequencing of Adult Glioma. *Molecular Cancer Therapeutics*, **2019**, 18, 991-1000	6.1	7
705	Detection of breast cancer stem cell gene mutations in circulating free DNA during the evolution of metastases. *Breast Cancer Research and Treatment*, **2019**, 178, 251-261	4.4	13
704	Suppression of p16 Induces mTORC1-Mediated Nucleotide Metabolic Reprogramming. *Cell Reports*, **2019**, 28, 1971-1980.e8	10.6	21
703	COTI-2, A Novel Thiosemicarbazone Derivative, Exhibits Antitumor Activity in HNSCC through p53-dependent and -independent Mechanisms. *Clinical Cancer Research*, **2019**, 25, 5650-5662	12.9	36
702	A Multi-center Study on the Reproducibility of Drug-Response Assays in Mammalian Cell Lines. *Cell Systems*, **2019**, 9, 35-48.e5	10.6	46
701	Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. *Breast Cancer Research*, **2019**, 21, 78	8.3	75
700	The phosphatase PPM1A inhibits triple negative breast cancer growth by blocking cell cycle progression. *Npj Breast Cancer*, **2019**, 5, 22	7.8	13
699	Transcriptional landscape and clinical utility of enhancer RNAs for eRNA-targeted therapy in cancer. *Nature Communications*, **2019**, 10, 4562	17.4	72
698	Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study. *Gynecologic Oncology*, **2019**, 155, 420-428	4.9	18
697	A-to-I-edited miRNA-379-5p inhibits cancer cell proliferation through CD97-induced apoptosis. *Journal of Clinical Investigation*, **2019**, 129, 5343-5356	15.9	25

696	Molecular mechanisms and pathobiology of oncogenic fusion transcripts in epithelial tumors. *Oncotarget*, **2019**, 10, 2095-2111	3.3	11
695	Combination of Ionizing Radiation with Glutaminase Inhibition Improves Treatment Response in Head and Neck Squamous Cell Carcinoma. *FASEB Journal*, **2019**, 33, 495.9	0.9	
694	Using Reverse Phase Protein Array (RPPA) to Identify and Target Adaptive Resistance. *Advances in Experimental Medicine and Biology*, **2019**, 1188, 251-266	3.6	5
693	Cooperative Effect of Oncogenic and in an HGF-Dominant Environment in Breast Cancer. *Molecular Cancer Therapeutics*, **2019**, 18, 399-412	6.1	5
692	Deregulated Gab2 phosphorylation mediates aberrant AKT and STAT3 signaling upon PIK3R1 loss in ovarian cancer. *Nature Communications*, **2019**, 10, 716	17.4	22
691	Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models. *Scientific Reports*, **2019**, 9, 1853	4.9	98
690	Genome-Wide Profiling of Acquired Uniparental Disomy Reveals Prognostic Factors in Head and Neck Squamous Cell Carcinoma. *Neoplasia*, **2019**, 21, 1102-1109	6.4	1
689	Expanded analysis of secondary germline findings from matched tumor/normal sequencing identifies additional clinically significant mutations. *JCO Precision Oncology*, **2019**, 3,	3.6	4
688	miRNA551b-3p Activates an Oncostatin Signaling Module for the Progression of Triple-Negative Breast Cancer. *Cell Reports*, **2019**, 29, 4389-4406.e10	10.6	36
687	MERIT: Systematic Analysis and Characterization of Mutational Effect on RNA Interactome Topology. *Hepatology*, **2019**, 70, 532-546	11.2	16
686	PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness. *Cancer Research*, **2019**, 79, 311-319	10.1	217
685	Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial Carcinoma. *Clinical Cancer Research*, **2019**, 25, 334-345	12.9	9
684	Genome-Wide Analysis of Head and Neck Squamous Cell Carcinomas Reveals HPV, TP53, Smoking and Alcohol-Related Allele-Based Acquired Uniparental Disomy Genomic Alterations. *Neoplasia*, **2019**, 21, 197-205	6.4	16
683	State-of-the-art strategies for targeting the DNA damage response in cancer. *Nature Reviews Clinical Oncology*, **2019**, 16, 81-104	19.4	412
682	Confocal Fluorescence Microscopy Platform Suitable for Rapid Evaluation of Small Fragments of Tissue in Surgical Pathology Practice. *Archives of Pathology and Laboratory Medicine*, **2019**, 143, 305-313	5	10
681	A-to-I RNA Editing Contributes to Proteomic Diversity in Cancer. *Cancer Cell*, **2018**, 33, 817-828.e7	24.3	91
680	EGFR-Phosphorylated Platelet Isoform of Phosphofructokinase 1 Promotes PI3K Activation. *Molecular Cell*, **2018**, 70, 197-210.e7	17.6	55
679	Multi-omics analysis reveals neoantigen-independent immune cell infiltration in copy-number driven cancers. *Nature Communications*, **2018**, 9, 1317	17.4	57

678	An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. *Cell*, **2018**, 173, 400-416.e11	56.2	1072
677	Comprehensive Characterization of Cancer Driver Genes and Mutations. *Cell*, **2018**, 173, 371-385.e18	56.2	854
676	Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. *Cell*, **2018**, 173, 291-304.e6	56.2	888
675	A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples. *Cell*, **2018**, 173, 386-399.e12	56.2	133
674	Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. *Cell*, **2018**, 173, 305-320.e10	56.2	166
673	Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. *Cell*, **2018**, 173, 338-354.e15	56.2	560
672	Oncogenic Signaling Pathways in The Cancer Genome Atlas. *Cell*, **2018**, 173, 321-337.e10	56.2	1124
671	Pathogenic Germline Variants in 10,389 Adult Cancers. *Cell*, **2018**, 173, 355-370.e14	56.2	342
670	Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types. *Cell Reports*, **2018**, 23, 282-296.e4	10.6	188
669	Driver Fusions and Their Implications in the Development and Treatment of Human Cancers. *Cell Reports*, **2018**, 23, 227-238.e3	10.6	235
668	Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. *Cell Reports*, **2018**, 23, 194-212.e6	10.6	146
667	Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context. *Cell Reports*, **2018**, 23, 297-312.e12	10.6	147
666	The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. *Cell Reports*, **2018**, 23, 313-326.e5	10.6	295
665	Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images. *Cell Reports*, **2018**, 23, 181-193.e7	10.6	366
664	The Immune Landscape of Cancer. *Immunity*, **2018**, 48, 812-830.e14	32.3	1754
663	Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas. *Cell Reports*, **2018**, 23, 172-180.e3	10.6	66
662	Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types. *Cell Reports*, **2018**, 23, 213-226.e3	10.6	56
661	Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. *Cell Reports*, **2018**, 23, 239-254.e6	10.6	405

660	Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers. *Cell Reports*, **2018**, 23, 255-269.e4	10.6	112
659	Systematic Analysis of Splice-Site-Creating Mutations in Cancer. *Cell Reports*, **2018**, 23, 270-281.e3	10.6	121
658	BRD4 facilitates replication stress-induced DNA damage response. *Oncogene*, **2018**, 37, 3763-3777	9.2	44
657	Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma. *EMBO Molecular Medicine*, **2018**, 10,	12	42
656	Rab25 augments cancer cell invasiveness through a β1 integrin/EGFR/VEGF-A/Snail signaling axis and expression of fascin. *Experimental and Molecular Medicine*, **2018**, 50, e435	12.8	26
655	Precision Oncology Decision Support: Current Approaches and Strategies for the Future. *Clinical Cancer Research*, **2018**, 24, 2719-2731	12.9	37
654	The Integrated Genomic Landscape of Thymic Epithelial Tumors. *Cancer Cell*, **2018**, 33, 244-258.e10	24.3	150
653	The Library of Integrated Network-Based Cellular Signatures NIH Program: System-Level Cataloging of Human Cells Response to Perturbations. *Cell Systems*, **2018**, 6, 13-24	10.6	199
652	Survival of Cancer Stem-Like Cells Under Metabolic Stress via CaMK2-mediated Upregulation of Sarco/Endoplasmic Reticulum Calcium ATPase Expression. *Clinical Cancer Research*, **2018**, 24, 1677-1690	12.9	22
651	Ex Vivo Confocal Fluorescence Microscopy for Rapid Evaluation of Tissues in Surgical Pathology Practice. *Archives of Pathology and Laboratory Medicine*, **2018**, 142, 396-401	5	25
650	Comprehensive Characterization of Alternative Polyadenylation in Human Cancer. *Journal of the National Cancer Institute*, **2018**, 110, 379-389	9.7	58
649	Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype. *Nature Communications*, **2018**, 9, 1777	17.4	116
648	Credentialing Individual Samples for Proteogenomic Analysis. *Molecular and Cellular Proteomics*, **2018**, 17, 1515-1530	7.6	3
647	Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. *Cell Systems*, **2018**, 6, 271-281.e7	10.6	320
646	Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. *Cell Systems*, **2018**, 6, 282-300.e2	10.6	159
645	lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer. *Cancer Cell*, **2018**, 33, 706-720.e9	24.3	275
644	Genomic and Functional Approaches to Understanding Cancer Aneuploidy. *Cancer Cell*, **2018**, 33, 676-689.e3	24.3	377
643	Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. *Cancer Cell*, **2018**, 33, 721-735.e8	24.3	228

642	A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. *Cancer Cell*, **2018**, 33, 690-705.e9	24.3	277
641	The Genomic Landscape and Pharmacogenomic Interactions of Clock Genes in Cancer Chronotherapy. *Cell Systems*, **2018**, 6, 314-328.e2	10.6	85
640	Implementation of a Multiplex and Quantitative Proteomics Platform for Assessing Protein Lysates Using DNA-Barcoded Antibodies. *Molecular and Cellular Proteomics*, **2018**, 17, 1245-1258	7.6	15
639	Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes. *Cell Systems*, **2018**, 6, 329-342.e6	10.6	36
638	Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma. *Clinical Cancer Research*, **2018**, 24, 4771-4784	12.9	21
637	BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency. *Cancer Cell*, **2018**, 33, 401-416.e8	24.3	138
636	Systematic Functional Annotation of Somatic Mutations in Cancer. *Cancer Cell*, **2018**, 33, 450-462.e10	24.3	114
635	Gene Regulatory Network Perturbation by Genetic and Epigenetic Variation. *Trends in Biochemical Sciences*, **2018**, 43, 576-592	10.3	10
634	Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients. *Cancer Cell*, **2018**, 34, 211-224.e6	24.3	327
633	BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors. *PLoS ONE*, **2018**, 13, e0200826	3.7	28
632	In vivo screening identifies GATAD2B as a metastasis driver in KRAS-driven lung cancer. *Nature Communications*, **2018**, 9, 2732	17.4	18
631	AKT isoform-specific expression and activation across cancer lineages. *BMC Cancer*, **2018**, 18, 742	4.8	18
630	ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. *Nature Medicine*, **2018**, 24, 556-562	50.5	227
629	Preclinical evaluation and reverse phase protein Array-based profiling of PI3K and MEK inhibitors in endometrial carcinoma in vitro. *BMC Cancer*, **2018**, 18, 168	4.8	12
628	Multi-nucleated cells use ROS to induce breast cancer chemo-resistance in vitro and in vivo. *Oncogene*, **2018**, 37, 4546-4561	9.2	40
627	Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. *Nature*, **2018**, 560, 382-386	50.4	1058
626	The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer. *EMBO Reports*, **2018**, 19,	6.5	20
625	Integrated Molecular Characterization of Testicular Germ Cell Tumors. *Cell Reports*, **2018**, 23, 3392-3406	10.6	200

624	-catenin/TCF activity regulates IGF-1R tyrosine kinase inhibitor sensitivity in colon cancer. *Oncogene*, **2018**, 37, 5466-5475	9.2	8
623	Cancer driver mutation prediction through Bayesian integration of multi-omic data. *PLoS ONE*, **2018**, 13, e0196939	3.7	8
622	Abstract CT033: Safety and early efficacy signals for COTI-2, an orally available small molecule targeting p53, in a phase I trial of recurrent gynecologic cancer **2018**,		4
621	Distinct histone modifications denote early stress-induced drug tolerance in cancer. *Oncotarget*, **2018**, 9, 8206-8222	3.3	39
620	Predicting high-risk endometrioid carcinomas using proteins. *Oncotarget*, **2018**, 9, 19704-19715	3.3	5
619	Physician interpretation of genomic test results and treatment selection. *Cancer*, **2018**, 124, 966-972	6.4	8
618	Surviving Ovarian Cancer: An Affair between Defective DNA Repair and RB1. *Clinical Cancer Research*, **2018**, 24, 508-510	12.9	10
617	Survival Outcomes by Mutation Status in Metastatic Breast Cancer. *JCO Precision Oncology*, **2018**, 2018,	3.6	23
616	Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies. *Nature Communications*, **2018**, 9, 4583	17.4	27
615	Loss of Phd2 cooperates with BRAF to drive melanomagenesis. *Nature Communications*, **2018**, 9, 5426	17.4	8
614	Implementing a comprehensive translational oncology platform: from molecular testing to actionability. *Journal of Translational Medicine*, **2018**, 16, 358	8.5	25
613	Modulation of the Hippo pathway and organ growth by RNA processing proteins. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, 10684-10689	11.5	7
612	Systems biology approach reveals a link between mTORC1 and G2/M DNA damage checkpoint recovery. *Nature Communications*, **2018**, 9, 3982	17.4	17
611	RNA editing derived epitopes function as cancer antigens to elicit immune responses. *Nature Communications*, **2018**, 9, 3919	17.4	54
610	A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF- Superfamily. *Cell Systems*, **2018**, 7, 422-437.e7	10.6	85
609	Personalized Integrated Network Modeling of the Cancer Proteome Atlas. *Scientific Reports*, **2018**, 8, 14924	4.9	6
608	Molecular determinants of post-mastectomy breast cancer recurrence. *Npj Breast Cancer*, **2018**, 4, 34	7.8	6
607	Integrative Molecular Characterization of Malignant Pleural Mesothelioma. *Cancer Discovery*, **2018**, 8, 1548-1565	24.4	258

606	Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer. *Cell Reports*, **2018**, 25, 1304-1317.e5	10.6	152
605	Defective Replication Stress Response Is Inherently Linked to the Cancer Stem Cell Phenotype. *Cell Reports*, **2018**, 23, 2095-2106	10.6	23
604	Cancer Cells Co-opt the Neuronal Redox-Sensing Channel TRPA1 to Promote Oxidative-Stress Tolerance. *Cancer Cell*, **2018**, 33, 985-1003.e7	24.3	113
603	Autotaxin exacerbates tumor progression by enhancing MEK1 and overriding the function of miR-489-3p. *Cancer Letters*, **2018**, 432, 84-92	9.9	10
602	Estrogen-related receptor gamma functions as a tumor suppressor in gastric cancer. *Nature Communications*, **2018**, 9, 1920	17.4	48
601	Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like Cells. *Clinical Cancer Research*, **2018**, 24, 4874-4886	12.9	35
600	Integrated genomic and molecular characterization of cervical cancer. *Nature*, **2017**, 543, 378-384	50.4	755
599	Context Specificity in Causal Signaling Networks Revealed by Phosphoprotein Profiling. *Cell Systems*, **2017**, 4, 73-83.e10	10.6	25
598	Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. *Cancer Cell*, **2017**, 31, 181-193	24.3	350
597	YAP/TAZ-Mediated Upregulation of GAB2 Leads to Increased Sensitivity to Growth Factor-Induced Activation of the PI3K Pathway. *Cancer Research*, **2017**, 77, 1637-1648	10.1	32
596	CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence. *Modern Pathology*, **2017**, 30, 1032-1041	9.8	116
595	Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays. *Cancer Cell*, **2017**, 31, 225-239	24.3	139
594	Epigenetic Regulation of KPC1 Ubiquitin Ligase Affects the NF-B Pathway in Melanoma. *Clinical Cancer Research*, **2017**, 23, 4831-4842	12.9	21
593	Molecular Diagnostics in Cancer **2017**, 1-14		2
592	Systematic characterization of A-to-I RNA editing hotspots in microRNAs across human cancers. *Genome Research*, **2017**, 27, 1112-1125	9.7	100
591	Identifying Abundant Immunotherapy and Other Targets in Solid Tumors: Integrating RNA-seq and Mass Spectrometry Proteomics Data Sets. *Cancer Journal (Sudbury, Mass.)*, **2017**, 23, 108-114	2.2	1
590	A murine preclinical syngeneic transplantation model for breast cancer precision medicine. *Science Advances*, **2017**, 3, e1600957	14.3	7
589	Engineering and Functional Characterization of Fusion Genes Identifies Novel Oncogenic Drivers of Cancer. *Cancer Research*, **2017**, 77, 3502-3512	10.1	22

588	Oncogenic RAS Regulates Long Noncoding RNA in Human Cancer. *Cancer Research*, **2017**, 77, 3745-3757	10.1	25
587	Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome Atlas. *JAMA Oncology*, **2017**, 3, 1654-1662	13.4	146
586	Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. *Cell*, **2017**, 169, 1327-1341.e23	56.2	1125
585	A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations. *Cancer Cell*, **2017**, 31, 820-832.e3	24.3	286
584	Molecular heterogeneity at the network level: high-dimensional testing, clustering and a TCGA case study. *Bioinformatics*, **2017**, 33, 2890-2896	7.2	10
583	Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer. *Clinical Cancer Research*, **2017**, 23, 5648-5656	12.9	38
582	Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in mutant cancers. *Science Translational Medicine*, **2017**, 9,	17.5	109
581	Functional variomics and network perturbation: connecting genotype to phenotype in cancer. *Nature Reviews Genetics*, **2017**, 18, 395-410	30.1	60
580	Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome. *Breast Cancer Research*, **2017**, 19, 44	8.3	57
579	Integrated Molecular Characterization of Uterine Carcinosarcoma. *Cancer Cell*, **2017**, 31, 411-423	24.3	210
578	Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. *Cell Reports*, **2017**, 18, 2780-2794	10.6	247
577	Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer. *Annals of Oncology*, **2017**, 28, 512-518	10.3	125
576	Role of RPL39 in Metaplastic Breast Cancer. *Journal of the National Cancer Institute*, **2017**, 109,	9.7	39
575	Precision oncology: neither a silver bullet nor a dream. *Pharmacogenomics*, **2017**, 18, 1525-1539	2.6	15
574	Explore, Visualize, and Analyze Functional Cancer Proteomic Data Using the Cancer Proteome Atlas. *Cancer Research*, **2017**, 77, e51-e54	10.1	50
573	A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors. *Clinical Cancer Research*, **2017**, 23, 6468-6477	12.9	31
572	Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. *Cell*, **2017**, 171, 540-556.e25	56.2	961
571	PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. *Nature*, **2017**, 550, 133-136	50.4	100

570	Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response. *Nature Communications*, **2017**, 8, 365	17.4	33
569	Clinical Use of Precision Oncology Decision Support. *JCO Precision Oncology*, **2017**, 2017,	3.6	15
568	ATG5 Mediates a Positive Feedback Loop between Wnt Signaling and Autophagy in Melanoma. *Cancer Research*, **2017**, 77, 5873-5885	10.1	20
567	A Unified Approach to Targeting the Lysosome's Degradative and Growth Signaling Roles. *Cancer Discovery*, **2017**, 7, 1266-1283	24.4	114
566	Stapled peptide inhibitors of RAB25 target context-specific phenotypes in cancer. *Nature Communications*, **2017**, 8, 660	17.4	34
565	Proteomic Features of Colorectal Cancer Identify Tumor Subtypes Independent of Oncogenic Mutations and Independently Predict Relapse-Free Survival. *Annals of Surgical Oncology*, **2017**, 24, 4051-4058	3.1	19
564	PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer. *Scientific Reports*, **2017**, 7, 10240	4.9	14
563	Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape. *Clinical Cancer Research*, **2017**, 23, 6686-6696	12.9	48
562	Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. *Cancer Cell*, **2017**, 32, 204-220.e15	24.3	391
561	Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. *Cancer Cell*, **2017**, 32, 185-203.e13	24.3	896
560	A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. *Cell Reports*, **2017**, 21, 1953-1967	10.6	89
559	"Personalized Cancer Therapy": A Publicly Available Precision Oncology Resource. *Cancer Research*, **2017**, 77, e123-e126	10.1	23
558	Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. *Cell*, **2017**, 171, 950-965.e28	56.2	451
557	Improved prediction of PARP inhibitor response and identification of synergizing agents through use of a novel gene expression signature generation algorithm. *Npj Systems Biology and Applications*, **2017**, 3, 8	5	34
556	Niche-localized tumor cells are protected from HER2-targeted therapy via upregulation of an anti-apoptotic program in vivo. *Npj Breast Cancer*, **2017**, 3, 18	7.8	14
555	Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4-NDRG1 Axis. *Cancer Research*, **2017**, 77, 86-99	10.1	43
554	Neomorphic mutations create therapeutic challenges in cancer. *Oncogene*, **2017**, 36, 1607-1618	9.2	19
553	Multiplatform-based molecular subtypes of non-small-cell lung cancer. *Oncogene*, **2017**, 36, 1384-1393	9.2	75

552	Loss-of-function screens of druggable targetome against cancer stem-like cells. *FASEB Journal*, **2017**, 31, 625-635	0.9	22
551	Next-Generation Sequencing and Result Interpretation in Clinical Oncology: Challenges of Personalized Cancer Therapy. *Annual Review of Medicine*, **2017**, 68, 113-125	17.4	25
550	RCP induces Slug expression and cancer cell invasion by stabilizing β1 integrin. *Oncogene*, **2017**, 36, 1102-1111	9.2	24
549	Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics. *Clinical Cancer Research*, **2017**, 23, 1263-1273	12.9	67
548	Musashi RNA-binding protein 2 regulates estrogen receptor 1 function in breast cancer. *Oncogene*, **2017**, 36, 1745-1752	9.2	39
547	Targeting KRas-dependent tumour growth, circulating tumour cells and metastasis in vivo by clinically significant miR-193a-3p. *Oncogene*, **2017**, 36, 1339-1350	9.2	35
546	Unique protein expression signatures of survival time in kidney renal clear cell carcinoma through a pan-cancer screening. *BMC Genomics*, **2017**, 18, 678	4.5	18
545	A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers. *JCI Insight*, **2017**, 2, e89760	9.9	49
544	Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer. *JCI Insight*, **2017**, 2, e90449	9.9	30
543	Multidimensional spatial characterization of the tumor microenvironment (TME) in synchronous melanoma metastases (SMM) to yield insights into mixed responses to therapy in metastatic melanoma (MM) patients (pts).. *Journal of Clinical Oncology*, **2017**, 35, 9575-9575	2.2	1
542	Characteristics of percutaneous core biopsies adequate for next generation genomic sequencing. *PLoS ONE*, **2017**, 12, e0189651	3.7	19
541	A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory. *Oncotarget*, **2017**, 8, 41806-41814	3.3	12
540	Genomic analysis of exceptional responder to regorafenib in treatment-refractory metastatic rectal cancer: a case report and review of the literature. *Oncotarget*, **2017**, 8, 57882-57888	3.3	8
539	Proteomic profiling of endometrioid endometrial cancer reveals differential expression of hormone receptors and MAPK signaling proteins in obese versus non-obese patients. *Oncotarget*, **2017**, 8, 106989-107001	3.3	7
538	Chk1 inhibition potentiates the therapeutic efficacy of PARP inhibitor BMN673 in gastric cancer. *American Journal of Cancer Research*, **2017**, 7, 473-483	4.4	22
537	Autotaxin, a lysophospholipase D with pleomorphic effects in oncogenesis and cancer progression. *Journal of Lipid Research*, **2016**, 57, 25-35	6.3	34
536	AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies. *Molecular Cancer Therapeutics*, **2016**, 15, 2563-2574	6.1	94
535	The rise of genomic profiling in ovarian cancer. *Expert Review of Molecular Diagnostics*, **2016**, 16, 1337-1358	3.8	14

534	ERK and p38 MAPK Activities Determine Sensitivity to PI3K/mTOR Inhibition via Regulation of MYC and YAP. *Cancer Research*, **2016**, 76, 7168-7180	10.1	40
533	Cardiac glycosides display selective efficacy for STK11 mutant lung cancer. *Scientific Reports*, **2016**, 6, 29721	4.9	24
532	Transgenic Expression of the Mitochondrial Chaperone TNFR-associated Protein 1 (TRAP1) Accelerates Prostate Cancer Development. *Journal of Biological Chemistry*, **2016**, 291, 25247-25254	5.4	19
531	Functional annotation of rare gene aberration drivers of pancreatic cancer. *Nature Communications*, **2016**, 7, 10500	17.4	47
530	Metabolic clusters of breast cancer in relation to gene- and protein expression subtypes. *Cancer & Metabolism*, **2016**, 4, 12	5.4	47
529	BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. *Molecular Cancer Therapeutics*, **2016**, 15, 1397-404	6.1	61
528	Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma. *Cell Reports*, **2016**, 14, 2476-89	10.6	228
527	Targeting therapeutic liabilities engendered by PIK3R1 mutations for cancer treatment. *Pharmacogenomics*, **2016**, 17, 297-307	2.6	24
526	Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance. *Cell*, **2016**, 164, 293-309	56.2	259
525	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). *Autophagy*, **2016**, 12, 1-222	10.2	3838
524	Glucose starvation induces mutation and lineage-dependent adaptive responses in a large collection of cancer cell lines. *International Journal of Oncology*, **2016**, 48, 67-72	4.4	6
523	Integrative Protein-Based Prognostic Model for Early-Stage Endometrioid Endometrial Cancer. *Clinical Cancer Research*, **2016**, 22, 513-23	12.9	19
522	Reply to M.P. Decatris et al. *Journal of Clinical Oncology*, **2016**, 34, 886	2.2	1
521	HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors. *Cancer Research*, **2016**, 76, 2720-30	10.1	25
520	Inferring causal molecular networks: empirical assessment through a community-based effort. *Nature Methods*, **2016**, 13, 310-8	21.6	158
519	Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. *Clinical Cancer Research*, **2016**, 22, 3764-73	12.9	438
518	Rab11-FIP1C Is a Critical Negative Regulator in ErbB2-Mediated Mammary Tumor Progression. *Cancer Research*, **2016**, 76, 2662-74	10.1	23
517	Proteomic Characterization of Head and Neck Cancer Patient-Derived Xenografts. *Molecular Cancer Research*, **2016**, 14, 278-86	6.6	41

516	Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies. *Clinical Cancer Research*, **2016**, 22, 1592-602	12.9	91
515	mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer. *Clinical Cancer Research*, **2016**, 22, 1699-712	12.9	65
514	Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. *New England Journal of Medicine*, **2016**, 374, 135-45	59.2	753
513	MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer. *Clinical Cancer Research*, **2016**, 22, 935-47	12.9	32
512	Clinical outcomes based on multigene profiling in metastatic breast cancer patients. *Oncotarget*, **2016**, 7, 76362-76373	3.3	18
511	Verteporfin inhibits YAP function through up-regulating 14-3-3 sequestering YAP in the cytoplasm. *American Journal of Cancer Research*, **2016**, 6, 27-37	4.4	85
510	The degree of intratumor mutational heterogeneity varies by primary tumor sub-site. *Oncotarget*, **2016**, 7, 27185-98	3.3	34
509	Rab25 acts as an oncogene in luminal B breast cancer and is causally associated with Snail driven EMT. *Oncotarget*, **2016**, 7, 40252-40265	3.3	28
508	Genomic-Glycosylation Aberrations in Tumor Initiation, Progression and Management. *AIMS Medical Science*, **2016**, 3, 386-416	0.4	1
507	The Novel Thiosemicarbazone Derivative Coti-2 Induces Mitochondrial Apoptosis in Acute Myeloid Leukemia Cells Via a p53-Independent Mechanism. *Blood*, **2016**, 128, 2757-2757	2.2	
506	Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. *Journal of Clinical Investigation*, **2016**, 126, 1834-56	15.9	167
505	Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion. *Breast Cancer Research and Treatment*, **2016**, 158, 441-54	4.4	18
504	The management of malignant ascites and impact on quality of life outcomes in women with ovarian cancer. *Expert Review of Quality of Life in Cancer Care*, **2016**, 1, 231-238		10
503	Hotspot mutations delineating diverse mutational signatures and biological utilities across cancer types. *BMC Genomics*, **2016**, 17 Suppl 2, 394	4.5	21
502	Patient derived mutation W257G of PPP2R1A enhances cancer cell migration through SRC-JNK-c-Jun pathway. *Scientific Reports*, **2016**, 6, 27391	4.9	19
501	Novel patient-derived xenograft and cell line models for therapeutic testing of pediatric liver cancer. *Journal of Hepatology*, **2016**, 65, 325-33	13.4	35
500	High Intratumoral Stromal Content Defines Reactive Breast Cancer as a Low-risk Breast Cancer Subtype. *Clinical Cancer Research*, **2016**, 22, 5068-5078	12.9	26
499	Phosphatase PTP4A3 Promotes Triple-Negative Breast Cancer Growth and Predicts Poor Patient Survival. *Cancer Research*, **2016**, 76, 1942-53	10.1	51

498	Cyclin E Associates with the Lipogenic Enzyme ATP-Citrate Lyase to Enable Malignant Growth of Breast Cancer Cells. *Cancer Research*, **2016**, 76, 2406-18	10.1	50
497	Yes-associated protein 1 and transcriptional coactivator with PDZ-binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma. *Hepatology*, **2016**, 63, 159-72	11.2	80
496	Direct Upregulation of STAT3 by MicroRNA-551b-3p Deregulates Growth and Metastasis of Ovarian Cancer. *Cell Reports*, **2016**, 15, 1493-1504	10.6	56
495	Comprehensive Characterization of Molecular Differences in Cancer between Male and Female Patients. *Cancer Cell*, **2016**, 29, 711-722	24.3	151
494	Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance. *Clinical Cancer Research*, **2016**, 22, 5238-5248	12.9	30
493	Using reverse-phase protein arrays as pharmacodynamic assays for functional proteomics, biomarker discovery, and drug development in cancer. *Seminars in Oncology*, **2016**, 43, 476-83	5.5	40
492	Integrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic Cancer. *Cell Reports*, **2016**, 16, 2017-31	10.6	65
491	The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platform. *Drug Discovery Today*, **2015**, 20, 1433-8	8.8	44
490	Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. *Cancer Discovery*, **2015**, 5, 860-77	24.4	476
489	Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma. *JAMA Oncology*, **2015**, 1, 486-94	13.4	27
488	Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. *New England Journal of Medicine*, **2015**, 372, 2481-98	59.2	1828
487	ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors. *Cancer Discovery*, **2015**, 5, 752-67	24.4	260
486	PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients. *Molecular Oncology*, **2015**, 9, 1694-703	7.9	40
485	Prognostic relevance of acquired uniparental disomy in serous ovarian cancer. *Molecular Cancer*, **2015**, 14, 29	42.1	13
484	Integrated analysis reveals microRNA networks coordinately expressed with key proteins in breast cancer. *Genome Medicine*, **2015**, 7, 21	14.4	24
483	Tubulin acetylation elevated in metastatic and basal-like breast cancer cells promotes microtentacle formation, adhesion, and invasive migration. *Cancer Research*, **2015**, 75, 203-15	10.1	114
482	The PI3K/AKT Pathway and Renal Cell Carcinoma. *Journal of Genetics and Genomics*, **2015**, 42, 343-53	4	197
481	Nuclear PTEN tumor-suppressor functions through maintaining heterochromatin structure. *Cell Cycle*, **2015**, 14, 2323-32	4.7	31

480	A decision support framework for genomically informed investigational cancer therapy. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	135
479	An Integrated Molecular Analysis of Lung Adenocarcinomas Identifies Potential Therapeutic Targets among TTF1-Negative Tumors, Including DNA Repair Proteins and Nrf2. *Clinical Cancer Research*, **2015**, 21, 3480-91	12.9	36
478	Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer. *Cancer Research*, **2015**, 75, 1091-101	10.1	53
477	The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers. *Cancer Cell*, **2015**, 28, 515-528	24.3	278
476	Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing. *American Journal of Clinical Pathology*, **2015**, 144, 713-21	1.9	26
475	Modulation of Breast Cancer Risk Biomarkers by High-Dose Omega-3 Fatty Acids: Phase II Pilot Study in Premenopausal Women. *Cancer Prevention Research*, **2015**, 8, 912-21	3.2	24
474	TransVar: a multilevel variant annotator for precision genomics. *Nature Methods*, **2015**, 12, 1002-3	21.6	40
473	Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. *Journal of Clinical Oncology*, **2015**, 33, 2753-62	2.2	295
472	Myristoylation confers noncanonical AMPK functions in autophagy selectivity and mitochondrial surveillance. *Nature Communications*, **2015**, 6, 7926	17.4	71
471	Comprehensive Genomic Characterization of Long Non-coding RNAs across Human Cancers. *Cancer Cell*, **2015**, 28, 529-540	24.3	465
470	Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. *Cell*, **2015**, 163, 506-19	56.2	1055
469	Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma. *JAMA Oncology*, **2015**, 1, 238-44	13.4	41
468	Modulation of Breast Cancer Risk Biomarkers by High-Dose Omega-3 Fatty Acids: Phase II Pilot Study in Postmenopausal Women. *Cancer Prevention Research*, **2015**, 8, 922-31	3.2	24
467	Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours. *Nature Communications*, **2015**, 6, 7419	17.4	125
466	Development of a robust classifier for quality control of reverse-phase protein arrays. *Bioinformatics*, **2015**, 31, 912-8	7.2	33
465	Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. *Clinical Cancer Research*, **2015**, 21, 1688-98	12.9	659
464	Cupid: simultaneous reconstruction of microRNA-target and ceRNA networks. *Genome Research*, **2015**, 25, 257-67	9.7	78
463	In silico prediction of physical protein interactions and characterization of interactome orphans. *Nature Methods*, **2015**, 12, 79-84	21.6	106

462	Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. *Journal of Investigative Dermatology*, **2015**, 135, 508-515	4.3	99
461	Genome-wide perturbations by miRNAs map onto functional cellular pathways, identifying regulators of chromatin modifiers. *Npj Systems Biology and Applications*, **2015**, 1, 15001	5	3
460	Injunctivitis: A blurring of the policing of protest or a vision of the way ahead?. *International Journal of Police Science and Management*, **2015**, 17, 128-133	0.8	1
459	Retrospective Review of MET Gene Mutations. *Oncoscience*, **2015**, 2, 533-41	0.8	28
458	SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	26
457	Regulation of glutamine carrier proteins by RNF5 determines breast cancer response to ER stress-inducing chemotherapies. *Cancer Cell*, **2015**, 27, 354-69	24.3	126
456	p85 neomorphic mutants: splitting away from the canonical path. *Molecular and Cellular Oncology*, **2015**, 2, e983388	1.2	1
455	Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations. *Cancer Research*, **2015**, 75, 5341-54	10.1	99
454	RET fusion as a novel driver of medullary thyroid carcinoma. *Journal of Clinical Endocrinology and Metabolism*, **2015**, 100, 788-93	5.6	55
453	Clinical actionability enhanced through deep targeted sequencing of solid tumors. *Clinical Chemistry*, **2015**, 61, 544-53	5.5	76
452	Death-associated protein kinase 1 promotes growth of p53-mutant cancers. *Journal of Clinical Investigation*, **2015**, 125, 2707-20	15.9	34
451	Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma. *Journal of Clinical Investigation*, **2015**, 125, 1459-70	15.9	84
450	Combined Homologous Recombination Deficiency (HRD) scores and response to neoadjuvant platinum-based chemotherapy in triple-negative and/or BRCA1/2 mutation-associated breast cancer.. *Journal of Clinical Oncology*, **2015**, 33, 1018-1018	2.2	1
449	Prevalence of incidental actionable germline mutations in 1,000 advanced cancer patients on a prospective somatic genomic profiling program.. *Journal of Clinical Oncology*, **2015**, 33, 1510-1510	2.2	4
448	Clinical characteristics and survival outcomes in BRCA1-methylated epithelial ovarian cancer (Bmeth-OC): A pooled analysis of data for 1,278 patients across five studies.. *Journal of Clinical Oncology*, **2015**, 33, 5526-5526	2.2	2
447	Phase II study of the PARP inhibitor talazoparib (BMN-673) in advanced cancer patients with somatic alterations in BRCA1/2, mutations/deletions in PTEN or PTEN loss, a homologous recombination defect, mutations/deletions in other BRCA pathway genes and germline mutation S in BRCA1/2 (not breast or ovarian cancer).. *Journal of Clinical Oncology*, **2015**, 33, TPS2617-TPS2617	2.2	5
446	Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer. *PLoS ONE*, **2015**, 10, e0133219	3.7	16
445	Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes. *PLoS ONE*, **2015**, 10, e0136851	3.7	39

444	Robust Selection Algorithm (RSA) for Multi-Omic Biomarker Discovery; Integration with Functional Network Analysis to Identify miRNA Regulated Pathways in Multiple Cancers. *PLoS ONE*, **2015**, 10, e0140072	3.7	8
443	Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients. *Oncotarget*, **2015**, 6, 1327-39	3.3	42
442	Functional consequence of the MET-T1010I polymorphism in breast cancer. *Oncotarget*, **2015**, 6, 2604-14	3.3	27
441	Homeostasis of redox status derived from glucose metabolic pathway could be the key to understanding the Warburg effect. *American Journal of Cancer Research*, **2015**, 5, 928-44	4.4	12
440	Homeostasis of redox status derived from glucose metabolic pathway could be the key to understanding the Warburg effect. *American Journal of Cancer Research*, **2015**, 5, 1265-80	4.4	9
439	Clinical next generation sequencing to identify actionable aberrations in a phase I program. *Oncotarget*, **2015**, 6, 20099-110	3.3	38
438	A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathway. *Oncotarget*, **2015**, 6, 41736-49	3.3	18
437	Regulation of the PI3K pathway through a p85 monomer-homodimer equilibrium. *ELife*, **2015**, 4, e06866	8.9	46
436	Mouse models of human PIK3CA-related brain overgrowth have acutely treatable epilepsy. *ELife*, **2015**, 4,	8.9	55
435	Ultra-deep next-generation sequencing of plasma cell-free (cf) DNA from patients with advanced cancers.. *Journal of Clinical Oncology*, **2015**, 33, e22168-e22168	2.2	
434	Proteomic signatures of colorectal cancer to identify distinct and reproducible subgroups and to reflect prognosis.. *Journal of Clinical Oncology*, **2015**, 33, 3612-3612	2.2	
433	Clinical outcomes based on multigene profiling in metastatic breast cancer patients.. *Journal of Clinical Oncology*, **2015**, 33, 1524-1524	2.2	
432	Development of a public knowledgebase to facilitate decision support for clinical cancer genomics reporting and clinical trial enrollment.. *Journal of Clinical Oncology*, **2015**, 33, e22163-e22163	2.2	
431	Enriched expression of PD-L1 and other immune targets after epithelial-mesenchymal transition (EMT) in squamous head and neck and lung cancers.. *Journal of Clinical Oncology*, **2015**, 33, 6016-6016	2.2	
430	Targeting ncRNAs in the 3q26.2 amplicon. *Oncoscience*, **2015**, 2, 671-2	0.8	1
429	Comparison of Mutation Profile Among Responders and Non-Responders in a Cohort of Patients with Relapsed/Refractory Myeloid Malignancies Treated with MEK 1/2 Inhibitor Trametinib. *Blood*, **2015**, 126, 1386-1386	2.2	
428	Cancer Systems Biology: a peek into the future of patient care?. *Nature Reviews Clinical Oncology*, **2014**, 11, 167-76	19.4	120
427	Genetic and pharmacological strategies to refunctionalize the von Hippel Lindau R167Q mutant protein. *Cancer Research*, **2014**, 74, 3127-36	10.1	18

426	Bias from removing read duplication in ultra-deep sequencing experiments. *Bioinformatics*, **2014**, 30, 1073-1080	7.2	30
425	Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma. *Journal of the National Cancer Institute*, **2014**, 106,	9.7	124
424	Reverse-phase protein array profiling of oropharyngeal cancer and significance of PIK3CA mutations in HPV-associated head and neck cancer. *Clinical Cancer Research*, **2014**, 20, 2300-11	12.9	73
423	Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions. *European Journal of Cancer*, **2014**, 50, 3003-10	7.5	55
422	Differences in gene and protein expression and the effects of race/ethnicity on breast cancer subtypes. *Cancer Epidemiology Biomarkers and Prevention*, **2014**, 23, 316-23	4	16
421	RADical response puts an exceptional responder in CHKmate: a synthetic lethal curative response to DNA-damaging chemotherapy?. *Cancer Discovery*, **2014**, 4, 988-90	24.4	3
420	Phosphorylation of ETS1 by Src family kinases prevents its recognition by the COP1 tumor suppressor. *Cancer Cell*, **2014**, 26, 222-34	24.3	51
419	Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. *Molecular and Cellular Proteomics*, **2014**, 13, 1690-704	7.6	239
418	Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. *Cell*, **2014**, 158, 929-944	56.2	935
417	A comprehensive evaluation of biomarkers predictive of response to PI3K inhibitors and of resistance mechanisms in head and neck squamous cell carcinoma. *Molecular Cancer Therapeutics*, **2014**, 13, 2738-50	6.1	62
416	A functional genomic approach identifies FAL1 as an oncogenic long noncoding RNA that associates with BMI1 and represses p21 expression in cancer. *Cancer Cell*, **2014**, 26, 344-357	24.3	303
415	PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. *Breast Cancer Research*, **2014**, 16, 406	8.3	199
414	Association between germline single nucleotide polymorphisms in the PI3K-AKT-mTOR pathway, obesity, and breast cancer disease-free survival. *Breast Cancer Research and Treatment*, **2014**, 147, 381-7	4.4	18
413	Assessing the clinical utility of cancer genomic and proteomic data across tumor types. *Nature Biotechnology*, **2014**, 32, 644-52	44.5	205
412	Genome-wide transcriptome profiling of homologous recombination DNA repair. *Nature Communications*, **2014**, 5, 3361	17.4	137
411	Promising rationally derived combination therapy with PI3K and CDK4/6 inhibitors. *Cancer Cell*, **2014**, 26, 7-9	24.3	7
410	Definition of PKC-╪CDK6, and MET as therapeutic targets in triple-negative breast cancer. *Cancer Research*, **2014**, 74, 4822-35	10.1	48
409	Concordance of genomic alterations between primary and recurrent breast cancer. *Molecular Cancer Therapeutics*, **2014**, 13, 1382-9	6.1	85

408	Influence of biospecimen variables on proteomic biomarkers in breast cancer. *Clinical Cancer Research*, **2014**, 20, 3870-83	12.9	41
407	A pan-cancer proteomic perspective on The Cancer Genome Atlas. *Nature Communications*, **2014**, 5, 3887	17.4	324
406	YB-1 transforms human mammary epithelial cells through chromatin remodeling leading to the development of basal-like breast cancer. *Stem Cells*, **2014**, 32, 1437-50	5.8	30
405	Gain-of-function mutant p53 promotes cell growth and cancer cell metabolism via inhibition of AMPK activation. *Molecular Cell*, **2014**, 54, 960-74	17.6	160
404	LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer. *Journal of Clinical Investigation*, **2014**, 124, 5490-502	15.9	26
403	A comprehensive comparison of normalization methods for loading control and variance stabilization of reverse-phase protein array data. *Cancer Informatics*, **2014**, 13, 109-17	2.4	17
402	Spatial normalization of reverse phase protein array data. *PLoS ONE*, **2014**, 9, e97213	3.7	18
401	AKT pathway genes define 5 prognostic subgroups in glioblastoma. *PLoS ONE*, **2014**, 9, e100827	3.7	9
400	cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer. *Journal of Cancer*, **2014**, 5, 745-53	4.5	32
399	Integrated analysis of transcriptomes of cancer cell lines and patient samples reveals STK11/LKB1-driven regulation of cAMP phosphodiesterase-4D. *Molecular Cancer Therapeutics*, **2014**, 13, 2463-73	6.1	10
398	Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 1114-9	11.5	62
397	A curated census of autophagy-modulating proteins and small molecules: candidate targets for cancer therapy. *Autophagy*, **2014**, 10, 1316-26	10.2	27
396	Unraveling the regulatory connections between two controllers of breast cancer cell fate. *Nucleic Acids Research*, **2014**, 42, 6839-49	20.1	7
395	Mig-6 suppresses endometrial cancer associated with Pten deficiency and ERK activation. *Cancer Research*, **2014**, 74, 7371-82	10.1	29
394	The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF. *Cancer Research*, **2014**, 74, 4845-4852	10.1	111
393	Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitors. *Cancer Cell*, **2014**, 26, 479-94	24.3	61
392	Integrated genomic characterization of papillary thyroid carcinoma. *Cell*, **2014**, 159, 676-90	56.2	1660
391	Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers. *Cancer Cell*, **2014**, 26, 863-879	24.3	34

390	A Bayesian hierarchical model for inference across related reverse phase protein arrays experiments. *Journal of Applied Statistics*, **2014**, 41, 2483-2492	1	
389	Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanoma. *Cancer Research*, **2014**, 74, 7037-47	10.1	126
388	Realizing the promise of reverse phase protein arrays for clinical, translational, and basic research: a workshop report: the RPPA (Reverse Phase Protein Array) society. *Molecular and Cellular Proteomics*, **2014**, 13, 1625-43	7.6	117
387	Proteomic characterization of breast cancer xenografts identifies early and late bevacizumab-induced responses and predicts effective drug combinations. *Clinical Cancer Research*, **2014**, 20, 404-12	12.9	27
386	A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition. *Cancer Research*, **2014**, 74, 15-23	10.1	47
385	Genomic copy number imbalances associated with bone and non-bone metastasis of early-stage breast cancer. *Breast Cancer Research and Treatment*, **2014**, 143, 189-201	4.4	6
384	Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance. *Journal of Clinical Investigation*, **2014**, 124, 2611-25	15.9	84
383	Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. *PLoS ONE*, **2014**, 9, e115383	3.7	276
382	Shrewd AKT regulation to survive. *Oncoscience*, **2014**, 1, 113-4	0.8	5
381	Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer. *Oncotarget*, **2014**, 5, 9049-64	3.3	18
380	Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors. *Oncotarget*, **2014**, 5, 8544-57	3.3	46
379	Activation of YAP1 is associated with poor prognosis and response to taxanes in ovarian cancer. *Anticancer Research*, **2014**, 34, 811-817	2.3	46
378	Implementation of biomarker-driven cancer therapy: existing tools and remaining gaps. *Discovery Medicine*, **2014**, 17, 101-14	2.5	35
377	Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer. *Cancer*, **2013**, 119, 7-15	6.4	43
376	EVI1 splice variants modulate functional responses in ovarian cancer cells. *Molecular Oncology*, **2013**, 7, 647-68	7.9	35
375	Mask is required for the activity of the Hippo pathway effector Yki/YAP. *Current Biology*, **2013**, 23, 229-36	9.3	58
374	BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation. *Molecular Oncology*, **2013**, 7, 567-79	7.9	100
373	Inferring tumour purity and stromal and immune cell admixture from expression data. *Nature Communications*, **2013**, 4, 2612	17.4	2572

372	PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells. *Cell*, **2013**, 155, 397-409	56.2	333
371	The somatic genomic landscape of glioblastoma. *Cell*, **2013**, 155, 462-77	56.2	2900
370	Repurposing the Pap smear: one step closer to gynecologic cancer screening. *Science Translational Medicine*, **2013**, 5, 167ps1	17.5	4
369	The Cancer Genome Atlas Pan-Cancer analysis project. *Nature Genetics*, **2013**, 45, 1113-20	36.3	3933
368	LKB1 is a central regulator of tumor initiation and pro-growth metabolism in ErbB2-mediated breast cancer. *Cancer & Metabolism*, **2013**, 1, 18	5.4	37
367	Favorable modulation of benign breast tissue and serum risk biomarkers is associated with > 10 % weight loss in postmenopausal women. *Breast Cancer Research and Treatment*, **2013**, 142, 119-32	4.4	46
366	Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. *Clinical Cancer Research*, **2013**, 19, 657-67	12.9	205
365	Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. *Cancer Discovery*, **2013**, 3, 761-9	24.4	414
364	Frequency-modulated pulses of ERK activity transmit quantitative proliferation signals. *Molecular Cell*, **2013**, 49, 249-61	17.6	317
363	High stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patients. *Breast Cancer Research and Treatment*, **2013**, 137, 319-27	4.4	67
362	The impact of tumor heterogeneity on patient treatment decisions. *Clinical Chemistry*, **2013**, 59, 38-40	5.5	7
361	Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. *Cell Reports*, **2013**, 4, 1116-30	10.6	447
360	EGFR mediates LPA-induced proteolytic enzyme expression and ovarian cancer invasion: inhibition by resveratrol. *Molecular Oncology*, **2013**, 7, 121-9	7.9	28
359	An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. *Clinical Cancer Research*, **2013**, 19, 279-90	12.9	649
358	Tat-activating regulatory DNA-binding protein regulates glycolysis in hepatocellular carcinoma by regulating the platelet isoform of phosphofructokinase through microRNA 520. *Hepatology*, **2013**, 58, 182-91	11.2	64
357	Integrated genomic characterization of endometrial carcinoma. *Nature*, **2013**, 497, 67-73	50.4	2800
356	Understanding the Functions of Lysophosphatidic Acid Receptors in Cancer **2013**, 641-659		
355	Influence of DNA copy number and mRNA levels on the expression of breast cancer related proteins. *Molecular Oncology*, **2013**, 7, 704-18	7.9	57

354	AMPK: a contextual oncogene or tumor suppressor?. *Cancer Research*, **2013**, 73, 2929-35	10.1	191
353	Building a personalized medicine infrastructure at a major cancer center. *Journal of Clinical Oncology*, **2013**, 31, 1849-57	2.2	85
352	TCPA: a resource for cancer functional proteomics data. *Nature Methods*, **2013**, 10, 1046-7	21.6	288
351	BSTA promotes mTORC2-mediated phosphorylation of Akt1 to suppress expression of FoxC2 and stimulate adipocyte differentiation. *Science Signaling*, **2013**, 6, ra2	8.8	34
350	Frequency of mutations and polymorphisms in borderline ovarian tumors of known cancer genes. *Modern Pathology*, **2013**, 26, 544-52	9.8	12
349	Perturbation biology: inferring signaling networks in cellular systems. *PLoS Computational Biology*, **2013**, 9, e1003290	5	98
348	Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer. *Clinical Cancer Research*, **2013**, 19, 6322-8	12.9	144
347	Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer. *Expert Opinion on Pharmacotherapy*, **2013**, 14, 2171-82	4	13
346	The Successes and Failures of Policing Animal Rights Extremism in the UK 2004–2010. *International Journal of Police Science and Management*, **2013**, 15, 30-44	0.8	6
345	Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. *Cancer Research*, **2013**, 73, 3470-80	10.1	289
344	Lactate dehydrogenase B: a metabolic marker of response to neoadjuvant chemotherapy in breast cancer. *Clinical Cancer Research*, **2013**, 19, 3703-13	12.9	78
343	A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. *Cancer Research*, **2013**, 73, 4885-97	10.1	331
342	Modeling precision treatment of breast cancer. *Genome Biology*, **2013**, 14, R110	18.3	204
341	Systematic identification of combinatorial drivers and targets in cancer cell lines. *PLoS ONE*, **2013**, 8, e60339	3.7	6
340	Small molecule ErbB inhibitors decrease proliferative signaling and promote apoptosis in philadelphia chromosome-positive acute lymphoblastic leukemia. *PLoS ONE*, **2013**, 8, e70608	3.7	18
339	Predicting time to ovarian carcinoma recurrence using protein markers. *Journal of Clinical Investigation*, **2013**, 123, 3740-50	15.9	42
338	Predicting time to ovarian carcinoma recurrence using protein markers. *Journal of Clinical Investigation*, **2013**, 123, 5410-5410	15.9	21
337	CanDrA: cancer-specific driver missense mutation annotation with optimized features. *PLoS ONE*, **2013**, 8, e77945	3.7	76

336	High risk CNIs, race and early stage breast cancer. *FASEB Journal*, **2013**, 27, 214.3	0.9	
335	A time-series DDP for functional proteomics profiles. *Biometrics*, **2012**, 68, 859-68	1.8	13
334	Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. *Gynecologic Oncology*, **2012**, 126, 47-53	4.9	62
333	Interactions between tumor cells and microenvironment in breast cancer: a new opportunity for targeted therapy. *Cancer Science*, **2012**, 103, 400-7	6.9	17
332	Reconstruction of nuclear receptor network reveals that NR2E3 is a novel upstream regulator of ESR1 in breast cancer. *EMBO Molecular Medicine*, **2012**, 4, 52-67	12	34
331	Rab25 increases cellular ATP and glycogen stores protecting cancer cells from bioenergetic stress. *EMBO Molecular Medicine*, **2012**, 4, 125-41	12	62
330	Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes. *Journal of Cancer Research and Clinical Oncology*, **2012**, 138, 377-85	4.9	47
329	Gene expression, molecular class changes, and pathway analysis after neoadjuvant systemic therapy for breast cancer. *Clinical Cancer Research*, **2012**, 18, 1109-19	12.9	50
328	Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. *Cell*, **2012**, 150, 780-91	56.2	1028
327	cMET and phospho-cMET protein levels in breast cancers and survival outcomes. *Clinical Cancer Research*, **2012**, 18, 2269-77	12.9	86
326	Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma. *Clinical Cancer Research*, **2012**, 18, 2278-89	12.9	61
325	EGR1 and the ERK-ERF axis drive mammary cell migration in response to EGF. *FASEB Journal*, **2012**, 26, 1582-92	0.9	70
324	Targeting the hepatocyte growth factor-cMET axis in cancer therapy. *Journal of Clinical Oncology*, **2012**, 30, 3287-96	2.2	226
323	Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. *Genome Research*, **2012**, 22, 2120-9	9.7	178
322	Bioinformatics and systems biology. *Molecular Oncology*, **2012**, 6, 147-54	7.9	17
321	Downregulation of SMG-1 in HPV-positive head and neck squamous cell carcinoma due to promoter hypermethylation correlates with improved survival. *Clinical Cancer Research*, **2012**, 18, 1257-67	12.9	67
320	Lysophosphatidic acid induces lymphangiogenesis and IL-8 production in vitro in human lymphatic endothelial cells. *American Journal of Pathology*, **2012**, 180, 2170-81	5.8	27
319	Overcoming implementation challenges of personalized cancer therapy. *Nature Reviews Clinical Oncology*, **2012**, 9, 542-8	19.4	96

318	Subtype and pathway specific responses to anticancer compounds in breast cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 2724-9	11.5	347
317	An efficient procedure for protein extraction from formalin-fixed, paraffin-embedded tissues for reverse phase protein arrays. *Proteome Science*, **2012**, 10, 56	2.6	48
316	An emerging toolkit for targeted cancer therapies. *Genome Research*, **2012**, 22, 177-82	9.7	18
315	Systematic analysis of genotype-specific drug responses in cancer. *International Journal of Cancer*, **2012**, 131, 2456-64	7.5	26
314	Detection algorithm for the validation of human cell lines. *International Journal of Cancer*, **2012**, 131, E1024-30	7.5	8
313	Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. *Nature Medicine*, **2012**, 18, 1052-9	50.5	177
312	Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. *Cancer Cell*, **2012**, 21, 227-39	24.3	309
311	Network analysis of the focal adhesion to invadopodia transition identifies a PI3K-PKC□ invasive signaling axis. *Science Signaling*, **2012**, 5, ra66	8.8	62
310	Rab25 in cancer: a brief update. *Biochemical Society Transactions*, **2012**, 40, 1404-8	5.1	50
309	LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients. *PLoS Genetics*, **2012**, 8, e1002538	6	28
308	Agents that stabilize mutated von Hippel-Lindau (VHL) protein: results of a high-throughput screen to identify compounds that modulate VHL proteostasis. *Journal of Biomolecular Screening*, **2012**, 17, 572-80		21
307	Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo. *Clinical Cancer Research*, **2012**, 18, 5911-23	12.9	49
306	PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. *Clinical Cancer Research*, **2012**, 18, 1777-89	12.9	174
305	Autotaxin expression from synovial fibroblasts is essential for the pathogenesis of modeled arthritis. *Journal of Experimental Medicine*, **2012**, 209, 925-33	16.6	118
304	Akt and ERK control the proliferative response of mammary epithelial cells to the growth factors IGF-1 and EGF through the cell cycle inhibitor p57Kip2. *Science Signaling*, **2012**, 5, ra19	8.8	59
303	Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing. *Modern Pathology*, **2012**, 25, 699-708	9.8	113
302	Autotaxin and its product lysophosphatidic acid suppress brown adipose differentiation and promote diet-induced obesity in mice. *Molecular Endocrinology*, **2012**, 26, 786-97		48
301	MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. *Journal of Experimental Medicine*, **2012**, 209, 679-96	16.6	252

300	Mechanistic basis for overcoming platinum resistance using copper chelating agents. *Molecular Cancer Therapeutics*, **2012**, 11, 2483-94	6.1	61
299	Biomarkers of response to Akt inhibitor MK-2206 in breast cancer. *Clinical Cancer Research*, **2012**, 18, 5816-28	12.9	120
298	Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. *Cancer Discovery*, **2012**, 2, 798-811	24.4	323
297	Dissecting "PI3Kness": the complexity of personalized therapy for ovarian cancer. *Cancer Discovery*, **2012**, 2, 16-8	24.4	27
296	Sparse Bayesian Graphical Models for RPPA Time Course Data **2012**, 2012, 113-117		1
295	Lysophosphatidic acid signaling protects pulmonary vasculature from hypoxia-induced remodeling. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2012**, 32, 24-32	9.4	26
294	AKT-dependent phosphorylation of Niban regulates nucleophosmin- and MDM2-mediated p53 stability and cell apoptosis. *EMBO Reports*, **2012**, 13, 554-60	6.5	50
293	Abortive autophagy induces endoplasmic reticulum stress and cell death in cancer cells. *PLoS ONE*, **2012**, 7, e39400	3.7	25
292	Somatic mutations of PIK3R1 promote gliomagenesis. *PLoS ONE*, **2012**, 7, e49466	3.7	40
291	DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance. *Neoplasia*, **2011**, 13, 1069-80	6.4	97
290	Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. *Nature Medicine*, **2011**, 17, 1498-503	50.5	1295
289	Astrocytes upregulate survival genes in tumor cells and induce protection from chemotherapy. *Neoplasia*, **2011**, 13, 286-98	6.4	184
288	Two phases of mitogenic signaling unveil roles for p53 and EGR1 in elimination of inconsistent growth signals. *Molecular Cell*, **2011**, 42, 524-35	17.6	85
287	Rab GTPases implicated in inherited and acquired disorders. *Seminars in Cell and Developmental Biology*, **2011**, 22, 57-68	7.5	73
286	Selective genomic copy number imbalances and probability of recurrence in early-stage breast cancer. *PLoS ONE*, **2011**, 6, e23543	3.7	36
285	Gene expression signature analysis identifies vorinostat as a candidate therapy for gastric cancer. *PLoS ONE*, **2011**, 6, e24662	3.7	83
284	Androgen regulation of 5□reductase isoenzymes in prostate cancer: implications for prostate cancer prevention. *PLoS ONE*, **2011**, 6, e28840	3.7	40
283	Rethinking ovarian cancer: recommendations for improving outcomes. *Nature Reviews Cancer*, **2011**, 11, 719-25	31.3	893

282	Location, location, location: a crystal-clear view of autotaxin saturating LPA receptors. *Nature Structural and Molecular Biology*, **2011**, 18, 117-8	17.6	19
281	Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer. *Clinical Proteomics*, **2011**, 8, 11	5	79
280	Benzyl and naphthalene methylphosphonic acid inhibitors of autotaxin with anti-invasive and anti-metastatic activity. *ChemMedChem*, **2011**, 6, 922-35	3.7	49
279	A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer. *Cancer Research*, **2011**, 71, 6773-84	10.1	125
278	Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. *Nature Medicine*, **2011**, 17, 1116-20	50.5	205
277	Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. *Cancer Research*, **2011**, 71, 1871-82	10.1	149
276	ER□dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. *Cancer Discovery*, **2011**, 1, 338-51	24.4	242
275	HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer. *Cancer Research* , **2011**, 71, 4412-22	10.1	132
274	Cross-species hybridization of microarrays for studying tumor transcriptome of brain metastasis. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 17456-61	11.5	94
273	ZNF668 functions as a tumor suppressor by regulating p53 stability and function in breast cancer. *Cancer Research*, **2011**, 71, 6524-34	10.1	22
272	A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance. *Clinical Cancer Research*, **2011**, 17, 2024-34	12.9	75
271	Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. *Clinical Cancer Research*, **2011**, 17, 1082-9	12.9	407
270	PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. *Molecular Cancer Therapeutics*, **2011**, 10, 1093-101	6.1	181
269	Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models. *Molecular Cancer Therapeutics*, **2011**, 10, 2350-62	6.1	188
268	High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. *Cancer Discovery*, **2011**, 1, 170-85	24.4	342
267	Small Molecule Inhibitors of HER2 Inhibit Proliferative Signaling and Promote Apoptosis in Ph+ ALL. *Blood*, **2011**, 118, 1397-1397	2.2	
266	Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges. *Journal of Oncology*, **2010**, 2010, 568938	4.5	89
265	Physical association of PDK1 with AKT1 is sufficient for pathway activation independent of membrane localization and phosphatidylinositol 3 kinase. *PLoS ONE*, **2010**, 5, e9910	3.7	33

264	Nicotinic acetylcholine receptor region on chromosome 15q25 and lung cancer risk among African Americans: a case-control study. *Journal of the National Cancer Institute*, **2010**, 102, 1199-205	9.7	54
263	CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis. *Clinical Cancer Research*, **2010**, 16, 3875-86	12.9	127
262	Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-beta pathway signaling indicates response to primary chemotherapy. *Clinical Cancer Research*, **2010**, 16, 2852-60	12.9	52
261	Activation of murine double minute 2 by Akt in mammary epithelium delays mammary involution and accelerates mammary tumorigenesis. *Cancer Research*, **2010**, 70, 7684-9	10.1	13
260	Aurora kinase A promotes ovarian tumorigenesis through dysregulation of the cell cycle and suppression of BRCA2. *Clinical Cancer Research*, **2010**, 16, 3171-81	12.9	92
259	Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set. *Molecular Cancer Therapeutics*, **2010**, 9, 257-67	6.1	74
258	PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 10208-13	11.5	293
257	Steroid receptor coactivator-3 expression in lung cancer and its role in the regulation of cancer cell survival and proliferation. *Cancer Research*, **2010**, 70, 6477-85	10.1	49
256	Mammalian target of rapamycin activator RHEB is frequently overexpressed in human carcinomas and is critical and sufficient for skin epithelial carcinogenesis. *Cancer Research*, **2010**, 70, 3287-98	10.1	133
255	ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 4153-8	11.5	532
254	Dose-dependent induction of distinct phenotypic responses to Notch pathway activation in mammary epithelial cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 5012-7	11.5	129
253	Rapamycin regulates stearoyl CoA desaturase 1 expression in breast cancer. *Molecular Cancer Therapeutics*, **2010**, 9, 2770-84	6.1	52
252	Are oncogenes sufficient to cause human cancer?. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 20599-600	11.5	4
251	Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. *Journal of Clinical Oncology*, **2010**, 28, 3570-6	2.2	290
250	Future of personalized medicine in oncology: a systems biology approach. *Journal of Clinical Oncology*, **2010**, 28, 2777-83	2.2	195
249	Activation of p21(CIP1/WAF1) in mammary epithelium accelerates mammary tumorigenesis and promotes lung metastasis. *Biochemical and Biophysical Research Communications*, **2010**, 403, 103-7	3.4	24
248	Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. *Breast Cancer Research*, **2010**, 12, R40	8.3	182
247	Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis. *Cancer Research*, **2010**, 70, 6704-14	10.1	161

246	Induction of papillary carcinoma in human ovarian surface epithelial cells using combined genetic elements and peritoneal microenvironment. *Cell Cycle*, **2010**, 9, 140-6	4.7	13
245	Proteomic profiling identifies pathways dysregulated in non-small cell lung cancer and an inverse association of AMPK and adhesion pathways with recurrence. *Journal of Thoracic Oncology*, **2010**, 5, 1894-904	8.9	50
244	A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers. *Clinical Proteomics*, **2010**, 6, 129-51	5	170
243	Reverse phase protein array identifies novel anti-invasion mechanisms of YC-1. *Biochemical Pharmacology*, **2010**, 79, 842-52	6	19
242	The rebirth of a phoenix: ovarian cancers are addicted to ErbB-3. *Cancer Cell*, **2010**, 17, 217-8	24.3	19
241	Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. *Cancer Cell*, **2010**, 18, 423-35	24.3	116
240	Synthesis and pharmacological evaluation of the stereoisomers of 3-carba cyclic-phosphatidic acid. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 7525-8	2.9	19
239	Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. *Journal of Clinical Investigation*, **2010**, 120, 2406-13	15.9	375
238	PTK6 regulates IGF-1-induced anchorage-independent survival. *PLoS ONE*, **2010**, 5, e11729	3.7	55
237	Messenger RNA expression and methylation of candidate tumor-suppressor genes and risk of ovarian cancer-a case-control analysis. *International Journal of Molecular Epidemiology and Genetics*, **2010**, 1, 1-10	0.9	19
236	Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. *Cancer Research*, **2009**, 69, 4116-24	10.1	674
235	Autotaxin/lysopholipase D and lysophosphatidic acid regulate murine hemostasis and thrombosis. *Journal of Biological Chemistry*, **2009**, 284, 7385-94	5.4	113
234	3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma. *Cancer Research*, **2009**, 69, 6299-306	10.1	106
233	A systems approach to analysis of molecular complexity in breast cancer. *Clinical Cancer Research*, **2009**, 15, 417-9	12.9	15
232	Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. *Cancer Research*, **2009**, 69, 4192-201	10.1	142
231	Phosphorylated 4E-BP1 is associated with poor survival in melanoma. *Clinical Cancer Research*, **2009** , 15, 2872-8	12.9	61
230	Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors. *Clinical Cancer Research*, **2009**, 15, 3396-405	12.9	56
229	Algorithmic guided screening of drug combinations of arbitrary size for activity against cancer cells. *Molecular Cancer Therapeutics*, **2009**, 8, 521-32	6.1	38

228	Intratumoral epidermal growth factor receptor antisense DNA therapy in head and neck cancer: first human application and potential antitumor mechanisms. *Journal of Clinical Oncology*, **2009**, 27, 1235-42	2.2	52
227	Cetuximab attenuates metastasis and u-PAR expression in non-small cell lung cancer: u-PAR and E-cadherin are novel biomarkers of cetuximab sensitivity. *Cancer Research*, **2009**, 69, 2461-70	10.1	23
226	ATX-LPA receptor axis in inflammation and cancer. *Cell Cycle*, **2009**, 8, 3695-701	4.7	84
225	Beta-arrestin/Ral signaling regulates lysophosphatidic acid-mediated migration and invasion of human breast tumor cells. *Molecular Cancer Research*, **2009**, 7, 1064-77	6.6	125
224	Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. *Molecular Cancer Therapeutics*, **2009**, 8, 2079-85	6.1	163
223	Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. *Cancer Research*, **2009**, 69, 143-50	10.1	250
222	Akt1 and akt2 play distinct roles in the initiation and metastatic phases of mammary tumor progression. *Cancer Research*, **2009**, 69, 5057-64	10.1	136
221	Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer. *Clinical Cancer Research*, **2009**, 15, 6852-61	12.9	84
220	Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. *Clinical Cancer Research*, **2009**, 15, 2472-8	12.9	169
219	Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor. *Molecular Cancer Therapeutics*, **2009**, 8, 1157-68	6.1	80
218	Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer. *Clinical Cancer Research*, **2009**, 15, 3654-62	12.9	109
217	Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. *Clinical Cancer Research*, **2009**, 15, 7538-7546	12.9	184
216	Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. *Cancer Research*, **2009**, 69, 565-72	10.1	304
215	Rak functions as a tumor suppressor by regulating PTEN protein stability and function. *Cancer Cell*, **2009**, 15, 304-14	24.3	152
214	Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. *Cancer Cell*, **2009**, 15, 539-50	24.3	299
213	AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. *Cancer Cell*, **2009**, 16, 21-32	24.3	432
212	Systems biology of breast cancer. *Current Breast Cancer Reports*, **2009**, 1, 238-245	0.8	2
211	Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. *Nature Genetics*, **2009**, 41, 991-5	36.3	270

210	Cadherin endocytosis. *Nature Reviews Cancer*, **2009**, 9, 143-143	31.3	19
209	The biology of ovarian cancer: new opportunities for translation. *Nature Reviews Cancer*, **2009**, 9, 415-28	31.3	1024
208	The emerging role of the RAB25 small GTPase in cancer. *Traffic*, **2009**, 10, 1561-8	5.7	68
207	PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth. *American Journal of Pathology*, **2009**, 174, 1869-79	5.8	40
206	Functional proteomic profiling of AML predicts response and survival. *Blood*, **2009**, 113, 154-64	2.2	195
205	Genomic amplicons target vesicle recycling in breast cancer. *Journal of Clinical Investigation*, **2009**, 119, 2123-7	15.9	29
204	Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis. *PLoS ONE*, **2009**, 4, e5583	3.7	35
203	Polymorphisms in the survivin promoter are associated with age of onset of ovarian cancer. *International Journal of Clinical and Experimental Medicine*, **2009**, 2, 289-99		20
202	ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. *Nature Cell Biology*, **2008**, 10, 138-48	23.4	515
201	Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. *Nature Genetics*, **2008**, 40, 616-22	36.3	1036
200	Derailed endocytosis: an emerging feature of cancer. *Nature Reviews Cancer*, **2008**, 8, 835-50	31.3	548
199	Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007. *Gynecologic Oncology*, **2008**, 108, 652-7	4.9	19
198	Lysophosphatidic acid (LPA)-induced vasodilator-stimulated phosphoprotein mediates lamellipodia formation to initiate motility in PC-3 prostate cancer cells. *Molecular Oncology*, **2008**, 2, 54-69	7.9	27
197	Overexpression of SnoN/SkiL, amplified at the 3q26.2 locus, in ovarian cancers: a role in ovarian pathogenesis. *Molecular Oncology*, **2008**, 2, 164-81	7.9	22
196	An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. *Cancer Research*, **2008**, 68, 6084-91	10.1	806
195	AMP-activated protein kinase signaling results in cytoplasmic sequestration of p27. *Cancer Research*, **2008**, 68, 6496-506	10.1	49
194	Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. *Cancer Research*, **2008**, 68, 3243-50	10.1	262
193	Monitoring autophagy in glioblastoma with antibody against isoform B of human microtubule-associated protein 1 light chain 3. *Autophagy*, **2008**, 4, 467-75	10.2	109

192	Autophagy: a novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model. *Cancer Research*, **2008**, 68, 7966-74	10.1	88
191	Mechanisms underlying p53 regulation of PIK3CA transcription in ovarian surface epithelium and in ovarian cancer. *Journal of Cell Science*, **2008**, 121, 664-74	5.3	63
190	Homozygous deletion of glycogen synthase kinase 3beta bypasses senescence allowing Ras transformation of primary murine fibroblasts. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 5248-53	11.5	18
189	Network topology determines dynamics of the mammalian MAPK1,2 signaling network: bifan motif regulation of C-Raf and B-Raf isoforms by FGFR and MC1R. *FASEB Journal*, **2008**, 22, 1393-403	0.9	15
188	A novel derivative of the natural agent deguelin for cancer chemoprevention and therapy. *Cancer Prevention Research*, **2008**, 1, 577-87	3.2	45
187	A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. *Cancer Research*, **2008**, 68, 206-15	10.1	250
186	Soft tissue sarcoma cells are highly sensitive to AKT blockade: a role for p53-independent up-regulation of GADD45 alpha. *Cancer Research*, **2008**, 68, 2895-903	10.1	45
185	Validation of reverse phase protein array for practical screening of potential biomarkers in serum and plasma: accurate detection of CA19-9 levels in pancreatic cancer. *Proteomics*, **2008**, 8, 3051-60	4.8	76
184	Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. *Molecular Carcinogenesis*, **2008**, 47, 701-6	5	218
183	The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. *Journal of Clinical Investigation*, **2008**, 118, 3917-29	15.9	298
182	Exploratory analysis of the copy number alterations in glioblastoma multiforme. *PLoS ONE*, **2008**, 3, e4076	3.7	33
181	Liquid chromatography mass spectrometry for quantifying plasma lysophospholipids: potential biomarkers for cancer diagnosis. *Methods in Enzymology*, **2007**, 433, 1-25	1.7	80
180	The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. *Nature Cell Biology*, **2007**, 9, 218-24	23.4	704
179	A module of negative feedback regulators defines growth factor signaling. *Nature Genetics*, **2007**, 39, 503-12	36.3	394
178	A new mutational AKTivation in the PI3K pathway. *Cancer Cell*, **2007**, 12, 104-7	24.3	210
177	A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. *Cancer Cell*, **2007**, 12, 395-402	24.3	1282
176	Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. *Clinical Cancer Research*, **2007**, 13, 5883-8	12.9	176
175	Telomere 3' overhang-specific DNA oligonucleotides induce autophagy in malignant glioma cells. *FASEB Journal*, **2007**, 21, 2918-30	0.9	55

174	Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt. *Cancer Research*, **2007**, 67, 5779-88	10.1	102
173	Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer. *Cancer Research*, **2007**, 67, 3074-84	10.1	102
172	Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells. *Cancer Research*, **2007**, 67, 684-94	10.1	156
171	Pharmacodynamic markers of perifosine efficacy. *Clinical Cancer Research*, **2007**, 13, 7421-31	12.9	107
170	Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer. *Molecular Cancer Therapeutics*, **2007**, 6, 1414-24	6.1	69
169	Knockdown of p53 combined with expression of the catalytic subunit of telomerase is sufficient to immortalize primary human ovarian surface epithelial cells. *Carcinogenesis*, **2007**, 28, 174-82	4.6	57
168	Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab. *Cancer Research*, **2007**, 67, 8240-7	10.1	135
167	Interaction of the Wiskott-Aldrich syndrome protein with sorting nexin 9 is required for CD28 endocytosis and cosignaling in T cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 1593-8	11.5	78
166	Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity. *Journal of Biological Chemistry*, **2007**, 282, 11221-9	5.4	637
165	Non-parametric quantification of protein lysate arrays. *Bioinformatics*, **2007**, 23, 1986-94	7.2	164
164	Rab25 associates with alpha5beta1 integrin to promote invasive migration in 3D microenvironments. *Developmental Cell*, **2007**, 13, 496-510	10.2	330
163	Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer. *Clinical Cancer Research*, **2007**, 13, 5745-55	12.9	301
162	Src promotes estrogen-dependent estrogen receptor alpha proteolysis in human breast cancer. *Journal of Clinical Investigation*, **2007**, 117, 2205-15	15.9	69
161	Overexpression of the Plasma Lysophospholipase D Autotaxin Reveals a Novel Pathway for Regulation of Hemostasis in Mice.. *Blood*, **2007**, 110, 3649-3649	2.2	1
160	Protein Expression Signatures Determined by Reverse Phase Proteins Arrays (RPPA) Accurately Predict FLT3-ITD Mutation Status in AML.. *Blood*, **2007**, 110, 2398-2398	2.2	
159	Molecular screening for breast cancer prevention, early detection, and treatment planning: combining biomarkers from DNA, RNA, and protein. *Current Oncology Reports*, **2006**, 8, 484-91	6.3	8
158	Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. *Cancer Cell*, **2006**, 9, 225-38	24.3	396
157	BRIT1 regulates early DNA damage response, chromosomal integrity, and cancer. *Cancer Cell*, **2006**, 10, 145-57	24.3	123

156	Point mutations of protein kinases and individualised cancer therapy. *Expert Opinion on Pharmacotherapy*, **2006**, 7, 2243-61	4	23
155	Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. *Clinical Cancer Research*, **2006**, 12, 3661-97	12.9	235
154	A retrovirus-based protein complementation assay screen reveals functional AKT1-binding partners. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 15014-9	11.5	76
153	Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia. *Cancer Research*, **2006**, 66, 3737-46	10.1	89
152	Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma. *Molecular Cancer Therapeutics*, **2006**, 5, 637-44	6.1	79
151	Assessing BRCA carrier probabilities in extended families. *Journal of Clinical Oncology*, **2006**, 24, 354-60	2.2	85
150	Carba analogs of cyclic phosphatidic acid are selective inhibitors of autotaxin and cancer cell invasion and metastasis. *Journal of Biological Chemistry*, **2006**, 281, 22786-93	5.4	125
149	Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. *Molecular Cancer Therapeutics*, **2006**, 5, 2512-21	6.1	526
148	Lysophosphatidic acid is a major regulator of growth-regulated oncogene alpha in ovarian cancer. *Cancer Research*, **2006**, 66, 2740-8	10.1	72
147	An inherent role of integrin-linked kinase-estrogen receptor alpha interaction in cell migration. *Cancer Research*, **2006**, 66, 11030-8	10.1	38
146	Of spiders and crabs: the emergence of lysophospholipids and their metabolic pathways as targets for therapy in cancer. *Clinical Cancer Research*, **2006**, 12, 6598-602	12.9	45
145	The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 16472-7	11.5	256
144	Phosphorylation of TNF-alpha converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 6901-6	11.5	122
143	Autophosphorylation of Akt at threonine 72 and serine 246. A potential mechanism of regulation of Akt kinase activity. *Journal of Biological Chemistry*, **2006**, 281, 13837-13843	5.4	23
142	mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. *Cancer Research*, **2006**, 66, 1500-8	10.1	2114
141	Differential roles of phosphoinositide-dependent protein kinase-1 and akt1 expression and phosphorylation in breast cancer cell resistance to Paclitaxel, Doxorubicin, and gemcitabine. *Molecular Pharmacology*, **2006**, 70, 1045-52	4.3	41
140	G-CSF induced reactive oxygen species involves Lyn-PI3-kinase-Akt and contributes to myeloid cell growth. *Blood*, **2006**, 107, 1847-56	2.2	113
139	Data integration gets 'Sloppy'. *Nature Biotechnology*, **2006**, 24, 1070-1	44.5	14

138	Identification of remodeling and spacing factor 1 (rsf-1, HBXAP) at chromosome 11q13 as a putative oncogene in ovarian cancer. *European Journal of Human Genetics*, **2006**, 14, 381-3	5.3	12
137	Inhibition of the phosphatidylinositol-3 kinase/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma. *British Journal of Haematology*, **2006**, 132, 503-11	4.5	78
136	High Throughput Proteomic Analysis of 559 Acute Myelogenous Leukemia (AML) Patient Samples on a Single Slide Using Reverse Phase Proteins Arrays (RPPA): Analysis of Signal Transduction Pathway (STP) and Apoptosis Regulating Proteins.. *Blood*, **2006**, 108, 107-107	2.2	2
135	Structure-activity relationships of fluorinated lysophosphatidic acid analogues. *Journal of Medicinal Chemistry*, **2005**, 48, 3319-27	8.3	69
134	Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. *Clinical Cancer Research*, **2005**, 11, 6116-26	12.9	250
133	Exploiting the PI3K/AKT pathway for cancer drug discovery. *Nature Reviews Drug Discovery*, **2005**, 4, 988-1004	64.1	1618
132	Emerging role of RAB GTPases in cancer and human disease. *Cancer Research*, **2005**, 65, 2516-9	10.1	176
131	Targeting integrin-linked kinase inhibits Akt signaling pathways and decreases tumor progression of human glioblastoma. *Molecular Cancer Therapeutics*, **2005**, 4, 1681-8	6.1	82
130	ZNF217 suppresses cell death associated with chemotherapy and telomere dysfunction. *Human Molecular Genetics*, **2005**, 14, 3219-25	5.6	48
129	Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 12519-24	11.5	206
128	Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity. *Cancer Research*, **2005**, 65, 1961-72	10.1	92
127	A Ras homologue member I directly inhibits signal transducers and activators of transcription 3 translocation and activity in human breast and ovarian cancer cells. *Cancer Research*, **2005**, 65, 6701-10	10.1	39
126	Assay of Rab25 function in ovarian and breast cancers. *Methods in Enzymology*, **2005**, 403, 202-15	1.7	35
125	Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancer. *Molecular Cancer Therapeutics*, **2005**, 4, 1146-56	6.1	76
124	Methylation and messenger RNA expression of p15INK4b but not p16INK4a are independent risk factors for ovarian cancer. *Clinical Cancer Research*, **2005**, 11, 4968-76	12.9	24
123	Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors. *Cancer Research*, **2005**, 65, 3336-46	10.1	471
122	Integrative epidemiology: from risk assessment to outcome prediction. *Journal of Clinical Oncology*, **2005**, 23, 267-75	2.2	53
121	Genes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signaling. *Journal of Biological Chemistry*, **2005**, 280, 2092-104	5.4	49

120	Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. *Molecular and Cellular Proteomics*, **2005**, 4, 346-55	7.6	244
119	Stem cell-ness: a "magic marker" for cancer. *Journal of Clinical Investigation*, **2005**, 115, 1463-7	15.9	27
118	Time Course Proteomic Profiling of Signal Transduction and Apoptosis Pathways in AML Survivor Cells Using Reverse Phase Protein Lysate Microarray (RPPA) Reveals Differential Effect of Time, Dose and Agent(s).. *Blood*, **2005**, 106, 1219-1219	2.2	1
117	Classification of Acute Myelogenous Leukemia (AML) Based on Patterns of Signal Transduction Pathway (STP) and Apoptosis Regulating Protein Activation Determined by Reverse Phase Proteins Arrays (RPPA).. *Blood*, **2005**, 106, 484-484	2.2	2
116	Therapeutic potential of phosphoinositide 3-kinase inhibitors. *Expert Opinion on Therapeutic Patents*, **2004**, 14, 703-732	6.8	32
115	Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. *Journal of Biological Chemistry*, **2004**, 279, 9653-61	5.4	153
114	Glycogen synthase kinase 3beta is a negative regulator of growth factor-induced activation of the c-Jun N-terminal kinase. *Journal of Biological Chemistry*, **2004**, 279, 51075-81	5.4	40
113	Lineage infidelity of MDA-MB-435 cells: expression of melanocyte proteins in a breast cancer cell line. *Cancer Research*, **2004**, 64, 3479-85	10.1	144
112	Determinants of rapamycin sensitivity in breast cancer cells. *Clinical Cancer Research*, **2004**, 10, 1013-23	12.9	254
111	A genetically defined model for human ovarian cancer. *Cancer Research*, **2004**, 64, 1655-63	10.1	233
110	The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. *Nature Medicine* , **2004**, 10, 1251-6	50.5	412
109	Molecular therapeutics: promise and challenges. *Seminars in Oncology*, **2004**, 31, 39-53	5.5	19
108	Lysophosphatidic acid production and action: validated targets in cancer?. *Journal of Cellular Biochemistry*, **2004**, 92, 1115-40	4.7	77
107	Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. *Clinical Cancer Research*, **2004**, 10, 3291-300	12.9	358
106	Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. *Clinical Cancer Research*, **2004**, 10, 7031-42	12.9	280
105	Differential Effects of Three Small Molecules Blocking Phosphatidylinositol-3 Kinase or AKT in Hodgkin Disease Cell Lines: Induction of Apoptosis and Cell Cycle Arrest.. *Blood*, **2004**, 104, 428-428	2.2	2
104	Mesenchymal Stem Cells Promote Survival of Leukemic Cells Via Integrin-Linked Kinase (ILK)-Dependent Akt and STAT3 Activation: Implications for Leukemia Therapy.. *Blood*, **2004**, 104, 3377-3377	2.2	
103	Modulators of lysophosphatidic acid signalling. *Expert Opinion on Therapeutic Patents*, **2003**, 13, 1619-1634	6.8	17

102	Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades. *Journal of Biological Chemistry*, **2003**, 278, 40057-66	5.4	189
101	Identification of a phosphothionate analogue of lysophosphatidic acid (LPA) as a selective agonist of the LPA3 receptor. *Journal of Biological Chemistry*, **2003**, 278, 11962-9	5.4	90
100	Transcriptional activation of the proglucagon gene by lithium and beta-catenin in intestinal endocrine L cells. *Journal of Biological Chemistry*, **2003**, 278, 1380-7	5.4	65
99	Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. *Journal of Biological Chemistry*, **2003**, 278, 19245-56	5.4	276
98	Evidence that phosphatidylinositol 3-kinase- and mitogen-activated protein kinase kinase-4/c-Jun NH2-terminal kinase-dependent Pathways cooperate to maintain lung cancer cell survival. *Journal of Biological Chemistry*, **2003**, 278, 23630-8	5.4	47
97	Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. *Molecular Endocrinology*, **2003**, 17, 575-88		186
96	Specific keynote: genome copy number abnormalities in ovarian cancer. *Gynecologic Oncology*, **2003**, 88, S16-21; discussion S22-4	4.9	29
95	Discussion: Metastasis and Angiogenesis in Epithelial Ovarian Cancer. *Gynecologic Oncology*, **2003**, 88, S37-S42	4.9	6
94	General keynote: molecular therapeutics and pharmocogenomics. *Gynecologic Oncology*, **2003**, 88, S84-7; discussion S93-6	4.9	2
93	Specific keynote: molecular therapeutics in ovarian cancer. *Gynecologic Oncology*, **2003**, 88, S88-92; discussion S93-6	4.9	21
92	Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. *Gynecologic Oncology*, **2003**, 88, 73-9	4.9	150
91	Overexpression of kallikrein 10 in epithelial ovarian carcinomas. *Gynecologic Oncology*, **2003**, 90, 44-50	4.9	59
90	Paclitaxel induces inactivation of p70 S6 kinase and phosphorylation of Thr421 and Ser424 via multiple signaling pathways in mitosis. *Oncogene*, **2003**, 22, 484-97	9.2	50
89	ARHI is a Ras-related small G-protein with a novel N-terminal extension that inhibits growth of ovarian and breast cancers. *Oncogene*, **2003**, 22, 2897-909	9.2	89
88	Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. *Oncogene*, **2003**, 22, 2812-22	9.2	409
87	HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. *Oncogene*, **2003**, 22, 3205-12	9.2	369
86	The emerging role of lysophosphatidic acid in cancer. *Nature Reviews Cancer*, **2003**, 3, 582-91	31.3	903
85	Enantioselective responses to a phosphorothioate analogue of lysophosphatidic acid with LPA3 receptor-selective agonist activity. *Journal of Medicinal Chemistry*, **2003**, 46, 5575-8	8.3	54

84	The human lipid phosphate phosphatase-3 decreases the growth, survival, and tumorigenesis of ovarian cancer cells: validation of the lysophosphatidic acid signaling cascade as a target for therapy in ovarian cancer. *Cancer Research*, **2003**, 63, 1073-82	10.1	100
83	Targeting the phosphatidylinositol 3-kinase/Akt pathway for enhancing breast cancer cells to radiotherapy. *Molecular Cancer Therapeutics*, **2003**, 2, 353-60	6.1	70
82	Autotaxin hydrolyzes sphingosylphosphorylcholine to produce the regulator of migration, sphingosine-1-phosphate. *Cancer Research*, **2003**, 63, 5446-53	10.1	174
81	Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer. *Clinical Cancer Research*, **2003**, 9, 3534-45	12.9	65
80	Evidence of haplotype insufficiency in human cells containing a germline mutation in BRCA1 or BRCA2. *International Journal of Cancer*, **2002**, 97, 557-61	7.5	77
79	Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-kappaB signaling. *Oncogene*, **2002**, 21, 1945-54	9.2	177
78	Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity. *Oncogene*, **2002**, 21, 2357-64	9.2	52
77	Identification of tissue- and cancer-selective promoters for the introduction of genes into human ovarian cancer cells. *Gynecologic Oncology*, **2002**, 85, 451-8	4.9	15
76	Convergence of multiple signaling cascades at glycogen synthase kinase 3: Edg receptor-mediated phosphorylation and inactivation by lysophosphatidic acid through a protein kinase C-dependent intracellular pathway. *Molecular and Cellular Biology*, **2002**, 22, 2099-110	4.8	147
75	Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. *Journal of the National Cancer Institute*, **2002**, 94, 844-51	9.7	124
74	Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. *Journal of Cell Biology*, **2002**, 158, 227-33	7.3	763
73	Use of proteomic patterns in serum to identify ovarian cancer. *Lancet, The*, **2002**, 359, 572-7	40	2653
72	Proteomic patterns in serum and identification of ovarian cancer. *Lancet, The*, **2002**, 360, 170-171	40	58
71	Mechanisms underlying chemoprevention of ovarian cancer. *Clinical Cancer Research*, **2002**, 8, 7-10	12.9	8
70	Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. *Cancer Research*, **2002**, 62, 1087-92	10.1	234
69	Inhibition of the phosphatidylinositol 3'-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. *Molecular Cancer Therapeutics*, **2002**, 1, 989-97	6.1	158
68	Heregulin-induced apoptosis is mediated by down-regulation of Bcl-2 and activation of caspase-7 and is potentiated by impairment of protein kinase C alpha activity. *Oncogene*, **2001**, 20, 8258-69	9.2	41
67	Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. *Journal of the National Cancer Institute*, **2001**, 93, 762-8	9.7	204

66	Defective cytochrome c-dependent caspase activation in ovarian cancer cell lines due to diminished or absent apoptotic protease activating factor-1 activity. *Journal of Biological Chemistry*, **2001**, 276, 34244-51	5.4	90
65	Tyrosine phosphorylation of p85 relieves its inhibitory activity on phosphatidylinositol 3-kinase. *Journal of Biological Chemistry*, **2001**, 276, 27455-61	5.4	194
64	Future for ovarian cancer screening: novel markers from emerging technologies of transcriptional profiling and proteomics. *Journal of the National Cancer Institute*, **2001**, 93, 1437-9	9.7	60
63	The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy. *Seminars in Oncology*, **2001**, 28, 125-141	5.5	72
62	Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer. *Annals of the New York Academy of Sciences*, **2000**, 905, 188-208	6.5	192
61	Analysis of the EDG2 receptor based on the structure/activity relationship of LPA. *Annals of the New York Academy of Sciences*, **2000**, 905, 279-81	6.5	5
60	Functional evidence for an ovarian cancer tumor suppressor gene on chromosome 22 by microcell-mediated chromosome transfer. *Oncogene*, **2000**, 19, 6277-85	9.2	8
59	A gonadotropin-releasing hormone-responsive phosphatase hydrolyses lysophosphatidic acid within the plasma membrane of ovarian cancer cells. *Journal of Clinical Endocrinology and Metabolism*, **2000**, 85, 3370-5	5.6	43
58	SHP-1 regulates Lck-induced phosphatidylinositol 3-kinase phosphorylation and activity. *Journal of Biological Chemistry*, **1999**, 274, 27583-9	5.4	125
57	PIK3CA is implicated as an oncogene in ovarian cancer. *Nature Genetics*, **1999**, 21, 99-102	36.3	955
56	Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway. *Oncogene*, **1999**, 18, 6635-40	9.2	226
55	Growth suppression of human ovarian cancer cell lines by the introduction of a p16 gene via a recombinant adenovirus. *Gynecologic Oncology*, **1999**, 73, 27-34	4.9	30
54	Adenovirus-mediated p53 growth inhibition of ovarian cancer cells is independent of endogenous p53 status. *Gynecologic Oncology*, **1999**, 75, 261-6	4.9	47
53	Markedly elevated levels of vascular endothelial growth factor in malignant ascites. *Annals of Surgical Oncology*, **1999**, 6, 373-8	3.1	212
52	The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells. *Oncogene*, **1999**, 18, 7034-45	9.2	261
51	Interleukin-2 reverses the defect in activation-induced apoptosis in T cells from autoimmune lpr mice. *Cellular Immunology*, **1998**, 183, 1-12	4.4	17
50	Expression of p16 induces transcriptional downregulation of the RB gene. *Oncogene*, **1998**, 16, 1-8	9.2	67
49	Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. *Current Biology*, **1998**, 8, 1195-8	6.3	407

48	p202 self-associates through a sequence conserved among the members of the 200-family proteins. *FEBS Letters*, **1998**, 438, 21-4	3.8	16
47	p202 prevents apoptosis in murine AKR-2B fibroblasts. *Biochemical and Biophysical Research Communications*, **1998**, 247, 379-82	3.4	24
46	Physiologic and pathologic drug resistance in ovarian carcinoma--a hypothesis based on a clonal progression model. *Acta Oncologica*, **1998**, 37, 629-40	3.2	16
45	Lysophosphatidylcholine stimulates activator protein 1 and the c-Jun N-terminal kinase activity. *Journal of Biological Chemistry*, **1997**, 272, 13683-9	5.4	63
44	Human hematopoietic cell express two forms of the cytokine receptor common gamma-chain (gamma c). *Cell Research*, **1997**, 7, 195-205	24.7	1
43	Src kinase activity is regulated by the SHP-1 protein-tyrosine phosphatase. *Journal of Biological Chemistry*, **1997**, 272, 21113-9	5.4	135
42	Reexpression of the retinoblastoma protein in tumor cells induces senescence and telomerase inhibition. *Oncogene*, **1997**, 15, 2589-96	9.2	134
41	Elevated levels and altered fatty acid composition of plasma lysophosphatidylcholine(lysoPC) in ovarian cancer patients. *International Journal of Cancer*, **1997**, 71, 31-4	7.5	126
40	Transfection of human ovarian cancer cells with the HER-2/neu receptor tyrosine kinase induces a selective increase in PTP-H1, PTP-1B, PTP-alpha expression. *Gynecologic Oncology*, **1996**, 61, 233-40	4.9	17
39	Cell cycle progression out of G1 sensitizes primary-cultured nontransformed T cells to TCR-mediated apoptosis. *Cellular Immunology*, **1996**, 170, 260-73	4.4	47
38	Functional LCK Is required for optimal CD28-mediated activation of the TEC family tyrosine kinase EMT/ITK. *Journal of Biological Chemistry*, **1996**, 271, 7079-83	5.4	59
37	Growth signal transduction by the human interleukin-2 receptor requires cytoplasmic tyrosines of the beta chain and non-tyrosine residues of the gamma c chain. *Journal of Biological Chemistry*, **1995**, 270, 21729-37	5.4	61
36	Fas (CD95) participates in peripheral T cell deletion and associated apoptosis in vivo. *International Immunology*, **1995**, 7, 1451-8	4.9	124
35	Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer. *Cancer*, **1995**, 76, 1615-20	6.4	16
34	Effect of lysophospholipids on signaling in the human Jurkat T cell line. *Journal of Cellular Physiology*, **1995**, 163, 441-50	7	76
33	Transforming growth factor-beta inhibits proliferation of human ovarian cancer cells obtained from ascites. *Cancer*, **1994**, 74, 93-9	6.4	58
32	The tyrosine kinase activity of the C-erbB-2 gene product (p185) is required for growth inhibition by anti-p185 antibodies but not for the cytotoxicity of an anti-p185-ricin-A chain immunotoxin. *International Journal of Cancer*, **1994**, 59, 242-7	7.5	14
31	Levels of soluble interleukin-2 receptor-alpha are elevated in serum and ascitic fluid from epithelial ovarian cancer patients. *American Journal of Obstetrics and Gynecology*, **1994**, 170, 918-28	6.4	21

30	Evidence that increases in lymphocyte tyrosine phosphorylation precede cardiac allograft rejection. Effects of cyclosporine and potential use in clinical management. *Transplantation*, **1994**, 58, 451-7	1.8	5
29	Introduction: Transmembrane signaling through hematopoietin receptors: interleukin-2 and erythropoietin. *Seminars in Immunology*, **1993**, 5, 297-298	10.7	6
28	Transmembrane signaling by the interleukin-2 receptor: progress and conundrums. *Seminars in Immunology*, **1993**, 5, 345-64	10.7	28
27	Role of aberrant sialylation of chronic myeloid leukemia granulocytes on binding and signal transduction by chemotactic peptides and colony stimulating factors. *Leukemia and Lymphoma*, **1993**, 11, 79-90	1.9	7
26	The v-raf oncogene enhances tumorigenicity and suppresses differentiation in vivo in a rat hepatocyte cell line. *Carcinogenesis*, **1993**, 14, 669-74	4.6	7
25	Neither the LCK nor the FYN kinases are obligatory for IL-2-mediated signal transduction in HTLV-I-infected human T cells. *International Immunology*, **1992**, 4, 1233-43	4.9	26
24	T-lymphocyte proliferation: tyrosine kinases in interleukin 2 signal transduction. *Best Practice and Research: Clinical Haematology*, **1992**, 5, 551-73		14
23	Immunogold labeling of the low-affinity (55 kd) IL2 receptor on the surface of IL2 receptor-bearing cultured cells and mitogen-activated peripheral blood lymphocytes. *Journal of Leukocyte Biology*, **1990**, 48, 213-9	6.5	3
22	Chapter 19 Activation of Lymphocytes by Lymphokines. *Current Topics in Membranes and Transport*, **1990**, 35, 495-535		3
21	Expression of ras oncogene leads to down-regulation of protein kinase C. *International Journal of Cancer*, **1990**, 45, 1177-83	7.5	28
20	Interrelationship between signals transduced by phytohemagglutinin and interleukin 1. *Journal of Cellular Physiology*, **1990**, 142, 539-51	7	13
19	Role of protein kinase C in interleukin 1, anti-T3, and mitogenic lectin-induced interleukin 2 secretion. *Journal of Cellular Physiology*, **1989**, 141, 310-7	7	12
18	Inhibition of stimulus-dependent epidermal growth factor receptor and transforming growth factor-alpha mRNA accumulation by the protein kinase C inhibitor staurosporine. *FEBS Letters*, **1989** , 243, 404-8	3.8	4
17	Increase of serum interleukin 2 receptor level in thermally injured patients. *Clinical Immunology and Immunopathology*, **1989**, 51, 205-15		38
16	Uptake of extracellular Ca2+ and not recruitment from internal stores is essential for T lymphocyte proliferation. *European Journal of Immunology*, **1988**, 18, 917-22	6.1	67
15	Interferon and phorbol esters down-regulate sIgM expression by independent pathways. *Journal of Cellular Physiology*, **1988**, 134, 245-52	7	5
14	Induction of competence and progression signals in human T lymphocytes by phorbol esters and calcium ionophores. *Journal of Cellular Physiology*, **1988**, 137, 329-36	7	31
13	Interleukin-2 induces proliferation of T lymphocyte mutants lacking protein kinase C. *Cell*, **1988**, 55, 91-100	36.2	136

12	Response of human B cells to different anti-immunoglobulin isotypes: absence of a correlation between early activation events and cell proliferation. *European Journal of Immunology*, **1987**, 17, 1737-42	6.1	14
11	Characterization of the role for calcium influx in mitogen-induced triggering of human T cells. Identification of calcium-dependent and calcium-independent signals. *European Journal of Immunology*, **1986**, 16, 907-12	6.1	81
10	Osmotic activation of the Na+/H+ antiport in protein kinase C-depleted lymphocytes. *Biochemical and Biophysical Research Communications*, **1986**, 134, 8-13	3.4	55
9	Lymphocyte function in human bone marrow. II. Characterization of an interleukin 2-sensitive T precursor-cell population. *Journal of Clinical Immunology*, **1985**, 5, 345-56	5.7	9
8	Mitogens trigger a calcium-independent signal for proliferation in phorbol-ester-treated lymphocytes. *Nature*, **1985**, 315, 419-20	50.4	84
7	Functional comparison of recombinant interleukin 2 (IL-2) with IL-2-containing preparations derived from cultured cells. *Cellular Immunology*, **1985**, 95, 146-56	4.4	15
6	Interleukin 2 in cell-mediated immune responses. *Journal of Supramolecular Structure*, **1980**, 13, 271-80		8
5	Cellular origins and targets of costimulator (IL2). *Immunological Reviews*, **1980**, 51, 157-75	11.3	50
4	Large-scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines		1
3	High multiplex, digital spatial profiling of proteins and RNA in fixed tissue using genomic detection methods		13
2	Adaptive response to BET inhibition induces therapeutic vulnerability to MCL1 inhibitors in breast cancer		1
1	Molecular targets for epithelial ovarian cancer606-618		